Chagas disease

Infectious Disease MONDO:0001444 Pathograph 13 Show in embeddings browser Neglected tropical disease Protozoal infection

Chagas disease (American trypanosomiasis) is a vector-borne protozoal infection caused by Trypanosoma cruzi, transmitted by triatomine insects, with an intracellular amastigote phase in human tissues and chronic cardiac morbidity.

Ask OpenScientist

Ask a research question about Chagas disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

6
Pathophys.
9
Phenotypes
3
Gaps
13
Pathograph
3
Medical Actions
2
Trials
21
References
1
Deep Research
🏷

Classifications

Harrison's Chapter
INFECTIOUS_DISEASES
?

Discussions and Knowledge Gaps

3
In chronic Chagas cardiomyopathy, how much of the ongoing myocardial injury is driven by persistent parasitism versus a self-sustaining autoimmune/ inflammatory process, and why does clearing parasitemia with benznidazole fail to halt cardiac deterioration once cardiomyopathy is established?
CONTROVERSY OPEN gap_chagas_persistence_vs_autoimmunity
Attached to
pathophysiology#Chronic myocardial inflammation and cardiomyopathy
The relative contributions of direct parasite persistence and of an immune-mediated (partly autoimmune) response to chronic Chagas cardiomyopathy are long debated. The BENEFIT trial sharpened the question: benznidazole significantly reduced serum parasite detection but did not reduce cardiac clinical deterioration over 5 years, implying that parasite clearance alone is insufficient once remodeling is established — consistent with a self-sustaining inflammatory/fibrotic process, an irreversibility threshold, or treatment given too late in the disease course.
Proposed experiments
Trypanocidal therapy timing versus myocardial fibrosis progression
prospective cohort study
exp_chagas_early_vs_late_trypanocidal
Compare benznidazole given in the indeterminate phase versus established cardiomyopathy, tracking cardiac MRI fibrosis, inflammatory biomarkers, and clinical outcomes to test whether an irreversibility threshold explains the BENEFIT null and to define the treatment window in which parasite clearance still alters cardiac trajectory.
Show evidence (1 reference)
PMID:26323937 SUPPORT Human Clinical
"The role of trypanocidal therapy in patients with established Chagas' cardiomyopathy is unproven."
The trial's premise and null clinical result frame the persistence-versus-autoimmunity and treatment-timing controversy.
Do implantable cardioverter-defibrillators and other novel therapies reduce mortality in Chagas cardiomyopathy, given the high burden of ventricular arrhythmias and sudden death?
KNOWLEDGE GAP OPEN gap_chagas_icd_rct
Attached to
phenotypes#Ventricular arrhythmia
Ventricular arrhythmias are a leading cause of death in Chagas cardiomyopathy, and ICDs are used in practice, but the mortality benefit specific to Chagas disease has not been established in adequately powered randomized trials.
Show evidence (1 reference)
PMID:20399979 SUPPORT Other
"the potential benefits of novel therapies (eg, implantable cardioverter defibrillators) need assessment in prospective randomised trials."
Authoritative review naming the ICD evidence gap for Chagas cardiomyopathy.
How does evolutionary remodeling of the chemosensory (odorant-receptor) repertoire in Rhodnius and other triatomine vectors drive adaptation from sylvatic to domestic (domiciliary) habitats, and can this be exploited for vector control to reduce human transmission?
KNOWLEDGE GAP OPEN gap_chagas_vector_chemosensory_domiciliation
Attached to
transmission#Triatomine fecal contamination during blood feeding
Vectorial transmission dominates human Chagas disease, and the key driver of human exposure is vector domiciliation (triatomines colonizing dwellings). A comparative-genomics preprint reports lineage-specific odorant-receptor expansions and shifts in selective constraint between sylvatic and domiciliary Rhodnius species, suggesting host-seeking/habitat-selection chemosensory remodeling underlies domiciliation. Whether these molecular signatures translate to behavioral domiciliation and offer control targets (e.g., attractants/repellents) is an open, translationally important question. Note: this lead rests on a non-peer-reviewed preprint and vector-evolution data rather than direct disease mechanism, so it is recorded as a gap rather than an asserted mechanism.
Show evidence (1 reference)
PPR:PPR1277623 SUPPORT Computational
"Several receptors, including Orco, also displayed shifts in selective constraints between sylvatic and domiciliary species, consistent with sensory remodeling associated with adaptation to domestic habitats."
Non-peer-reviewed comparative-genomics preprint (in silico evolutionary analysis) reporting chemosensory remodeling linked to domiciliary adaptation; cited as a knowledge-gap lead, not as sole support for a disease-mechanism claim.
⚙

Pathophysiology

6
Intracellular amastigote replication in host cells
Metacyclic trypomastigotes invade host cells and differentiate into amastigotes that proliferate intracellularly.
Downstream
Chronic Th1 myocarditis and parasite persistence Persistent parasitism of cardiac tissue drives chronic inflammatory myocardial injury.
Enteric nervous system denervation Parasitism of the digestive tract drives destruction of enteric neurons.
Show evidence (1 reference)
PMID:18512345 SUPPORT In Vitro
"Metacyclic trypomastigotes promptly invade host cells (including gastric mucosa) and once free in the cytoplasm, differentiate into amastigotes that replicate by binary fission."
The abstract describes intracellular invasion and amastigote replication.
Chronic Th1 myocarditis and parasite persistence
Low-grade parasite persistence in the myocardium sustains a chronic interferon-gamma/TNF-alpha-rich Th1 myocarditis over decades. Persistence is supported by the BENEFIT trial, in which the majority of patients with established chronic cardiomyopathy were PCR-positive for the parasite at baseline; about 30% of infected patients eventually develop chronic Chagas cardiomyopathy.
cardiac muscle cell CL:0000746
inflammatory response GO:0006954 ↑ INCREASED
Downstream
Cardiomyocyte mitochondrial dysfunction Sustained IFN-gamma/TNF-alpha signaling impairs cardiomyocyte mitochondrial energetics.
Show evidence (2 references)
DOI:10.1177/15353702231220658 SUPPORT Human Clinical
"a Th1-T cell rich myocarditis with abundant interferon (IFN)-γ and tumor necrosis factor (TNF)-α"
Identifies the chronic IFN-gamma/TNF-alpha-rich Th1 myocarditis that drives chronic Chagas cardiomyopathy.
PMID:26323937 SUPPORT Human Clinical
"60.5% had positive results for Trypanosoma cruzi on PCR."
Documents ongoing parasite persistence (PCR positivity) in the majority of patients with established chronic Chagas cardiomyopathy.
Cardiomyocyte mitochondrial dysfunction
The constitutively upregulated IFN-gamma and TNF-alpha signaling of chronic Chagas myocarditis suppresses mitochondrial energy metabolism in cardiomyocytes, lowering high-energy phosphate/ATP production and impairing contractile and electrical function.
cardiac muscle cell CL:0000746
mitochondrion organization GO:0007005 ↓ DECREASED
Downstream
Myocardial fibrosis and arrhythmogenic substrate Inflammatory and metabolic injury drives fibrotic remodeling and an arrhythmia substrate.
Show evidence (1 reference)
DOI:10.1177/15353702231220658 SUPPORT Human Clinical
"IFN-γ and TNF-α signaling, which are constitutively upregulated in CD patients, negatively affect mitochondrial function in cardiomyocytes, recapitulating findings in CCC heart tissue."
Documents cytokine-driven cardiomyocyte mitochondrial dysfunction as a distinct step in CCC pathogenesis.
Myocardial fibrosis and arrhythmogenic substrate
Chronic inflammation, mitochondrial dysfunction, and cardiomyocyte loss produce myocardial fibrosis (excess extracellular matrix), which together with these injuries forms the substrate for re-entrant ventricular arrhythmias and progressive ventricular remodeling.
cardiac muscle cell CL:0000746
extracellular matrix organization GO:0030198 ↑ INCREASED
Downstream
Ventricular remodeling and dilated cardiomyopathy Fibrotic injury drives maladaptive ventricular remodeling.
Ventricular arrhythmia The fibrotic substrate underlies re-entrant ventricular arrhythmias.
Show evidence (1 reference)
DOI:10.1177/15353702231220658 SUPPORT Human Clinical
"Myocardial fibrosis, inflammation, and mitochondrial dysfunction are involved in the arrhythmia substrate and triggering events."
Identifies fibrosis (with inflammation and mitochondrial dysfunction) as the arrhythmogenic substrate.
Ventricular remodeling and dilated cardiomyopathy
Cumulative fibrosis and cardiomyocyte loss produce maladaptive ventricular remodeling and dilated cardiomyopathy — the hallmark chronic manifestation — with heart failure and arrhythmia as the fatal endpoints.
cardiac muscle cell CL:0000746
cardiac muscle tissue morphogenesis GO:0055008 ⚠ ABNORMAL
Downstream
Cardiomyopathy The remodeling cascade manifests clinically as Chagas cardiomyopathy.
Show evidence (1 reference)
DOI:10.1177/15353702231220658 SUPPORT Human Clinical
"Death results from heart failure or arrhythmia in a subset of CCC patients."
Identifies heart failure and arrhythmia as the fatal endpoints of the remodeling cascade.
Enteric nervous system denervation
Inflammatory invasion of the enteric plexuses causes progressive destruction of myenteric (Auerbach) neurons throughout the digestive tract. The resulting intrinsic denervation impairs peristalsis and, in a subset of patients, produces the digestive megasyndromes (megaesophagus and megacolon).
neuron apoptotic process GO:0051402 ↑ INCREASED
Downstream
Megaesophagus Esophageal denervation produces megaesophagus.
Megacolon Colonic denervation produces megacolon.
Show evidence (2 references)
PMID:20004942 SUPPORT Human Clinical
"Gastrointestinal form of Chagas disease involves an inflammatory invasion of the enteric plexuses and degeneration of enteric neurons"
Human pathology study documenting inflammatory enteric-plexus invasion and neuronal degeneration as the digestive-form mechanism.
PMID:32338024 SUPPORT Human Clinical
"the digestive form is characterized by megaesophagus and megacolon. There is altered peristalsis due to the destruction of the neurons of the enteric nervous system caused by the parasite."
Links enteric-neuron destruction to impaired peristalsis and the megaesophagus/megacolon megasyndromes.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Chagas disease Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

9
Cardiovascular 5
Cardiomyopathy FREQUENT Cardiomyopathy HP:0001638
Show evidence (2 references)
DOI:10.1177/15353702231220658 SUPPORT Human Clinical
"About 30% of CD patients develop chronic Chagas disease cardiomyopathy"
About 30% of chronically infected patients develop chronic Chagas cardiomyopathy, placing it in the FREQUENT band (30-79%).
PMID:28284779 SUPPORT Human Clinical
"Chagas cardiomyopathy (CC) is one of the chronic manifestations of Trypanosoma cruzi (T. cruzi) infection"
The abstract identifies cardiomyopathy as a chronic manifestation of Chagas disease.
Heart failure Congestive heart failure HP:0001635
Show evidence (1 reference)
PMID:28284779 SUPPORT Human Clinical
"Chagas etiology of heart failure has become the third most common indication for HT in South America."
The abstract links Chagas disease to heart failure requiring transplantation.
Myocarditis Myocarditis HP:0012819
Show evidence (1 reference)
PMID:25993972 SUPPORT Other
"In the acute phase, the disease can cause cardiac derangements such as myocarditis, conduction system abnormalities, and/or pericarditis."
Review documenting acute myocarditis as an acute-phase cardiac manifestation.
Atrioventricular block Atrioventricular block HP:0001678
Show evidence (1 reference)
PMID:25993972 SUPPORT Other
"In the acute phase, the disease can cause cardiac derangements such as myocarditis, conduction system abnormalities, and/or pericarditis."
Review documenting conduction-system abnormalities (including AV block) as a cardiac manifestation of Chagas disease.
Ventricular arrhythmia Ventricular arrhythmia HP:0004308
Show evidence (1 reference)
PMID:25993972 SUPPORT Other
"Up to one-half of these patients will develop a cardiomyopathy, which can lead to cardiac failure and/or ventricular arrhythmias, both of which are major causes of mortality."
Review linking chronic cardiomyopathy to ventricular arrhythmias and mortality.
Digestive 2
Megacolon Megacolon HP:6000852
Show evidence (1 reference)
PMID:32338024 SUPPORT Human Clinical
"the digestive form is characterized by megaesophagus and megacolon. There is altered peristalsis due to the destruction of the neurons of the enteric nervous system caused by the parasite."
Case report documenting megacolon as part of the digestive form of Chagas disease.
Constipation Constipation HP:0002019
Show evidence (1 reference)
PMID:32338024 SUPPORT Human Clinical
"constipation refractory to medical treatment, in the context of megacolon due to Chagas disease"
Case report documenting refractory constipation from chagasic megacolon.
Other 2
Bundle branch and fascicular block Bundle branch block HP:0011710
Show evidence (1 reference)
PMID:28056014 SUPPORT Human Clinical
"including right bundle branch block (RBBB), left anterior or posterior fascicular block (LAFB or LPFB, respectively)"
Documents RBBB with fascicular block as the characteristic early conduction abnormality of Chagas heart disease.
Megaesophagus Abnormal esophagus morphology HP:0002031
Granularity note: HPO has no megaesophagus-specific term (as of this curation), so this is bound to the closest available parent, HP:0002031 Abnormal esophagus morphology; a more specific term would warrant a new-term request to HPO. This contrasts with megacolon, which has a specific term (HP:6000852).
Show evidence (1 reference)
PMID:20004942 SUPPORT Human Clinical
"the innervation of the esophageal muscle was substantially reduced in patients with megaesophagus"
Human study documenting megaesophagus with reduced esophageal innervation.
💊

Medical Actions

3
Benznidazole or nifurtimox antitrypanosomal therapy
Action: Pharmacotherapy NCIT:C15986
Agent: benznidazole CHEBI:133833 nifurtimox CHEBI:7566
Antiparasitic therapy with benznidazole or nifurtimox, the only two WHO-recognized trypanocidal drugs. Efficacy is highest in the acute phase, congenital infection, and early chronic (indeterminate) infection; in established chronic cardiomyopathy the BENEFIT trial showed it clears parasitemia but does not halt cardiac deterioration.
Mechanism Target:
INHIBITS Intracellular amastigote replication in host cells — Trypanocidal drugs kill replicating T. cruzi, reducing parasite load.
Show evidence (3 references)
PMID:30111183 SUPPORT Other
"Currently, only benznidazole (BZN) and nifurtimox are recognized by the World Health Organization as effective drugs for treatment of CD."
The review lists benznidazole and nifurtimox as WHO-recognized therapies.
PMID:20399979 SUPPORT Other
"treatment with benznidazole (or nifurtimox) is reasonably safe and effective, and is now recommended for a widened range of patients."
Review supporting benznidazole/nifurtimox as reasonably safe and effective for a widened patient range.
PMID:26323937 PARTIAL Human Clinical
"Trypanocidal therapy with benznidazole in patients with established Chagas' cardiomyopathy significantly reduced serum parasite detection but did not significantly reduce cardiac clinical deterioration through 5 years of follow-up."
BENEFIT randomized trial; benznidazole cleared parasitemia but did not slow cardiac deterioration in established cardiomyopathy, bounding the benefit of trypanocidal therapy in that setting.
Chagas cardiomyopathy management
Action: Pharmacotherapy NCIT:C15986
Agent: amiodarone CHEBI:2663
Symptomatic cardiac management for established Chagas heart disease: standard heart-failure therapy, amiodarone for ventricular arrhythmias, and consideration of an implantable cardioverter-defibrillator; advanced disease may require heart transplantation.
Mechanism Target:
INHIBITS Myocardial fibrosis and arrhythmogenic substrate — Amiodarone suppresses arrhythmias arising from the fibrotic substrate, and ICDs abort sudden death from them; neither reverses the substrate itself.
Show evidence (1 reference)
PMID:25993972 SUPPORT Other
"The treatment of Chagas cardiac disease comprises standard medical therapy for heart failure and amiodarone for ventricular arrhythmias, with consideration for implantable cardioverter-defibrillator."
Review describing the standard symptomatic management of Chagas heart disease.
Heart transplantation
Action: organ transplantation Ontology label: Organ Transplantation NCIT:C15289
Orthotopic heart transplantation is the definitive therapy for end-stage Chagas cardiomyopathy; Chagas disease is now a leading indication for heart transplantation in South America.
Mechanism Target:
INHIBITS Ventricular remodeling and dilated cardiomyopathy — Transplantation replaces the end-stage remodeled heart.
Show evidence (1 reference)
PMID:28284779 SUPPORT Human Clinical
"Chagas etiology of heart failure has become the third most common indication for HT in South America."
Documents heart transplantation as a major treatment for end-stage Chagas cardiomyopathy.
🌍

Environmental Factors

1
Domestic triatomine vector control
Large-scale insecticide-based triatomine (kissing-bug) vector control, together with blood-donor screening, has reduced Chagas disease incidence and prevalence and is the principal translational target for interrupting vectorial transmission (see the vector chemosensory/domiciliation knowledge gap).
Show evidence (1 reference)
PMID:20399979 SUPPORT Other
"Large-scale vector control programmes and screening of blood donors have reduced disease incidence and prevalence."
Authoritative review documenting vector control (and blood-donor screening) as effective transmission-reduction interventions.
🔬

Clinical Trials

2
NCT03378661 PHASE_II
BENDITA — proof-of-concept randomized trial of benznidazole monotherapy at reduced doses/durations and benznidazole/E1224 (fosravuconazole) combination regimens in adults with chronic indeterminate Chagas disease.
Show evidence (1 reference)
clinicaltrials:NCT03378661 SUPPORT Human Clinical
"the assessment of new BZN-sparing regimens in monotherapy and in combination with E1224."
Trial evaluating improved/shorter benznidazole regimens to address current treatment limitations.
NCT04897516 PHASE_III
NuestroBen — Phase III non-inferiority trial testing shorter (14- and 28-day) benznidazole regimens versus the standard 60-day course in adults with chronic Chagas disease, aiming to improve the safety profile.
Show evidence (1 reference)
clinicaltrials:NCT04897516 SUPPORT Human Clinical
"NuestroBen will test the hypothesis that shorter treatment regimens of 14 days and 28 days will be non-inferior to the standard 60-day treatment while improving the safety profile."
Trial testing whether shorter benznidazole regimens retain efficacy with better tolerability.
{ }

Source YAML

click to show 
name: Chagas disease
creation_date: '2026-01-26T15:56:41Z'
updated_date: '2026-04-11T00:41:29Z'
category: Infectious Disease
description: >-
  Chagas disease (American trypanosomiasis) is a vector-borne protozoal infection
  caused by Trypanosoma cruzi, transmitted by triatomine insects, with an
  intracellular amastigote phase in human tissues and chronic cardiac morbidity.
disease_term:
  term:
    id: MONDO:0001444
    label: Chagas disease
  preferred_term: Chagas disease
classifications:
  harrisons_chapter:
  - classification_value: INFECTIOUS_DISEASES
    evidence:
    - reference: PMID:20399979
      reference_title: "Chagas disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Chagas disease is a chronic, systemic, parasitic infection caused by the protozoan Trypanosoma cruzi, and was discovered in 1909."
      explanation: Authoritative review classifying Chagas disease as a systemic protozoal (parasitic infectious) disease.
prevalence:
- population: Latin America
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 1212.0
  notes: >-
    Rassi et al. estimated ~8 million people infected in Latin America; other
    contemporary reviews cite 6-7 million. Endemic across 21 continental Latin
    American countries, with growing case numbers in non-endemic regions
    (USA/Europe) driven by migration. Rate derived as ~8,000,000 cases over a
    Latin American population of ~660 million (~1.2% = 1212/100,000).
  evidence:
  - reference: PMID:20399979
    reference_title: "Chagas disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The disease affects about 8 million people in Latin America, of whom 30-40% either have or will develop cardiomyopathy, digestive megasyndromes, or both."
    explanation: Provides the widely cited ~8 million Latin American burden estimate.
parents:
- Neglected tropical disease
- Protozoal infection
infectious_agent:
- name: Trypanosoma cruzi
  infectious_agent_term:
    preferred_term: Trypanosoma cruzi
    term:
      id: NCBITaxon:5693
      label: Trypanosoma cruzi
  description: Kinetoplastid protozoan parasite that causes Chagas disease.
  evidence:
  - reference: PMID:34207491
    reference_title: "Mechanisms Associated with Trypanosoma cruzi Host Target Cell Adhesion, Recognition and Internalization."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Chagas disease is caused by the kinetoplastid parasite Trypanosoma cruzi"
    explanation: The review identifies Trypanosoma cruzi as the causative agent.
agent_life_cycle:
  description: Trypanosoma cruzi alternates between triatomine insect vectors and mammalian hosts.
  hosts:
  - preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
    role: definitive host
  - preferred_term: triatomine bug
    term:
      id: NCBITaxon:70999
      label: Triatominae
    role: intermediate host
  vectors:
  - triatomine bugs (Triatominae)
  life_cycle_stages:
  - name: Epimastigote stage in triatomine vectors
    life_cycle_stage_term:
      preferred_term: Trypanosoma cruzi epimastigote stage
      term:
        id: OPL:0000223
        label: Trypanosoma cruzi epimastigote stage
    description: Epimastigotes are the non-infective forms in triatomine vectors.
    evidence:
    - reference: PMID:28919885
      reference_title: "Trypanosoma cruzi Evades the Complement System as an Efficient Strategy to Survive in the Mammalian Host: The Specific Roles of Host/Parasite Molecules and Trypanosoma cruzi Calreticulin."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Epimastigotes, the non-infective form of the parasite, present in triatomine arthropod vectors"
      explanation: The abstract locates epimastigotes in triatomine vectors.
  - name: Metacyclic trypomastigote stage in vector feces
    life_cycle_stage_term:
      preferred_term: Trypanosoma cruzi metacyclic trypomastigote stage
      term:
        id: OPL:0000131
        label: Trypanosoma cruzi metacyclic trypomastigote stage
    description: Metacyclic trypomastigotes in triatomine feces initiate infection.
    evidence:
    - reference: PMID:18512345
      reference_title: "Host cell actin remodeling in response to Trypanosoma cruzi: trypomastigote versus amastigote entry."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "infected triatomines release in their feces highly motile and infective metacyclic trypomastigotes that may initiate infection"
      explanation: The abstract describes infective metacyclic trypomastigotes released in vector feces.
  - name: Bloodstream trypomastigote stage
    life_cycle_stage_term:
      preferred_term: Trypanosoma cruzi trypomastigote stage
      term:
        id: OPL:0000169
        label: Trypanosoma cruzi trypomastigote stage
    description: Trypomastigotes circulate in host blood as infective forms.
    evidence:
    - reference: PMID:28919885
      reference_title: "Trypanosoma cruzi Evades the Complement System as an Efficient Strategy to Survive in the Mammalian Host: The Specific Roles of Host/Parasite Molecules and Trypanosoma cruzi Calreticulin."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "trypomastigotes, the infective form, present in host bloodstream"
      explanation: The abstract identifies trypomastigotes in host bloodstream.
  - name: Intracellular amastigote stage
    life_cycle_stage_term:
      preferred_term: Trypanosoma cruzi amastigote stage
      term:
        id: OPL:0000064
        label: Trypanosoma cruzi amastigote stage
    description: Amastigotes differentiate in host cells and replicate by binary fission.
    evidence:
    - reference: PMID:18512345
      reference_title: "Host cell actin remodeling in response to Trypanosoma cruzi: trypomastigote versus amastigote entry."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "differentiate into amastigotes that replicate by binary fission"
      explanation: The abstract reports amastigote differentiation and replication in host cells.
transmission:
- name: Triatomine fecal contamination during blood feeding
  description: >-
    The dominant route: infected triatomines release metacyclic trypomastigotes
    in feces during blood meals, which enter through the bite wound or mucosa. In
    a large chronic-CD cohort, vectorial transmission accounted for ~91% of cases.
  evidence:
  - reference: PMID:18512345
    reference_title: "Host cell actin remodeling in response to Trypanosoma cruzi: trypomastigote versus amastigote entry."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "While feeding on host's blood, infected triatomines release in their feces highly motile and infective metacyclic trypomastigotes that may initiate infection."
    explanation: The abstract links transmission to triatomine blood feeding and fecal contamination.
  - reference: PMID:40531676
    reference_title: "Association between transmission modes and chronic Chagas disease clinical forms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "vectorial in 1962 (90.8%) patients, followed by blood transfusion in 123 (5.7%), congenital in 59 (2.7%)"
    explanation: Cohort data quantifying the relative frequency of transmission modes in chronic Chagas disease.
- name: Congenital (vertical) transmission
  description: >-
    Trypanosoma cruzi can be transmitted from an infected mother to the fetus
    transplacentally, an increasingly important route in both endemic and
    non-endemic (migration-affected) settings.
  evidence:
  - reference: PMID:25993972
    reference_title: "The Epidemiology, Clinical Manifestations, and Management of Chagas Heart Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "T cruzi is most commonly transmitted through the feces of an infected triatomine, but can also be congenital, via contaminated blood transfusion or through direct oral contact."
    explanation: Review documenting congenital, transfusion, and oral routes in addition to the dominant vectorial route.
- name: Transfusion and organ-transplant transmission
  description: >-
    Blood transfusion and organ transplantation transmit T. cruzi; blood-donor
    screening has substantially reduced this route in endemic countries.
  evidence:
  - reference: PMID:40531676
    reference_title: "Association between transmission modes and chronic Chagas disease clinical forms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "vectorial in 1962 (90.8%) patients, followed by blood transfusion in 123 (5.7%), congenital in 59 (2.7%)"
    explanation: Cohort data quantifying transfusion as a transmission mode in chronic Chagas disease.
- name: Oral transmission via contaminated food or drink
  description: >-
    Ingestion of food or beverages contaminated with infected triatomine feces
    (e.g., acai, sugarcane juice) causes oral outbreaks, notably in Amazonian
    regions.
  evidence:
  - reference: PMID:25993972
    reference_title: "The Epidemiology, Clinical Manifestations, and Management of Chagas Heart Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "T cruzi is most commonly transmitted through the feces of an infected triatomine, but can also be congenital, via contaminated blood transfusion or through direct oral contact."
    explanation: Review documenting oral transmission as an additional route.
progression:
- phase: Acute phase
  duration: Weeks to a few months after infection
  notes: >-
    Often mild or asymptomatic; can cause an acute febrile illness with
    myocarditis, conduction abnormalities, or pericarditis, and (rarely) severe
    acute myocarditis or meningoencephalitis. A chagoma or Romana sign may mark
    the inoculation site.
  evidence:
  - reference: PMID:25993972
    reference_title: "The Epidemiology, Clinical Manifestations, and Management of Chagas Heart Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In the acute phase, the disease can cause cardiac derangements such as myocarditis, conduction system abnormalities, and/or pericarditis."
    explanation: Documents the acute-phase clinical manifestations.
- phase: Indeterminate (asymptomatic chronic) form
  duration: Years to lifelong
  notes: >-
    After the acute phase most infected people enter the indeterminate form —
    seropositive but without symptoms or detectable cardiac/digestive
    involvement. About 60% remain in this form indefinitely and never progress.
  evidence:
  - reference: DOI:10.1177/15353702231220658
    reference_title: "Inflammation and mitochondria in the pathogenesis of chronic Chagas disease cardiomyopathy"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "while most infected patients (60%) remain asymptomatic in the so-called indeterminate form (IF)."
    explanation: Establishes the indeterminate form as the outcome for the majority of infected patients.
- phase: Chronic symptomatic phase (cardiac and/or digestive)
  duration: Decades after infection
  notes: >-
    In roughly 30-40% of infected people the disease advances, over decades, to
    chronic Chagas cardiomyopathy and/or the digestive megasyndromes
    (megaesophagus, megacolon).
  evidence:
  - reference: PMID:25993972
    reference_title: "The Epidemiology, Clinical Manifestations, and Management of Chagas Heart Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "If left untreated, the disease advances to the chronic phase."
    explanation: Documents progression from acute/indeterminate to the chronic phase.
  - reference: PMID:20399979
    reference_title: "Chagas disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The disease affects about 8 million people in Latin America, of whom 30-40% either have or will develop cardiomyopathy, digestive megasyndromes, or both."
    explanation: Quantifies the ~30-40% who develop chronic cardiac and/or digestive disease.
pathophysiology:
- name: Intracellular amastigote replication in host cells
  biological_scale: CELLULAR
  description: Metacyclic trypomastigotes invade host cells and differentiate into amastigotes that proliferate intracellularly.
  evidence:
  - reference: PMID:18512345
    reference_title: "Host cell actin remodeling in response to Trypanosoma cruzi: trypomastigote versus amastigote entry."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Metacyclic trypomastigotes promptly invade host cells (including gastric mucosa) and once free in the cytoplasm, differentiate into amastigotes that replicate by binary fission."
    explanation: The abstract describes intracellular invasion and amastigote replication.
  downstream:
  - target: Chronic Th1 myocarditis and parasite persistence
    description: Persistent parasitism of cardiac tissue drives chronic inflammatory myocardial injury.
  - target: Enteric nervous system denervation
    description: Parasitism of the digestive tract drives destruction of enteric neurons.
- name: Chronic Th1 myocarditis and parasite persistence
  biological_scale: TISSUE
  description: >-
    Low-grade parasite persistence in the myocardium sustains a chronic
    interferon-gamma/TNF-alpha-rich Th1 myocarditis over decades. Persistence is
    supported by the BENEFIT trial, in which the majority of patients with
    established chronic cardiomyopathy were PCR-positive for the parasite at
    baseline; about 30% of infected patients eventually develop chronic Chagas
    cardiomyopathy.
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  biological_processes:
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: DOI:10.1177/15353702231220658
    reference_title: "Inflammation and mitochondria in the pathogenesis of chronic Chagas disease cardiomyopathy"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a Th1-T cell rich myocarditis with abundant interferon (IFN)-γ and tumor necrosis factor (TNF)-α"
    explanation: Identifies the chronic IFN-gamma/TNF-alpha-rich Th1 myocarditis that drives chronic Chagas cardiomyopathy.
  - reference: PMID:26323937
    reference_title: "Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "60.5% had positive results for Trypanosoma cruzi on PCR."
    explanation: Documents ongoing parasite persistence (PCR positivity) in the majority of patients with established chronic Chagas cardiomyopathy.
  downstream:
  - target: Cardiomyocyte mitochondrial dysfunction
    description: Sustained IFN-gamma/TNF-alpha signaling impairs cardiomyocyte mitochondrial energetics.
- name: Cardiomyocyte mitochondrial dysfunction
  biological_scale: CELLULAR
  description: >-
    The constitutively upregulated IFN-gamma and TNF-alpha signaling of chronic
    Chagas myocarditis suppresses mitochondrial energy metabolism in
    cardiomyocytes, lowering high-energy phosphate/ATP production and impairing
    contractile and electrical function.
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  biological_processes:
  - preferred_term: mitochondrion organization
    modifier: DECREASED
    term:
      id: GO:0007005
      label: mitochondrion organization
  evidence:
  - reference: DOI:10.1177/15353702231220658
    reference_title: "Inflammation and mitochondria in the pathogenesis of chronic Chagas disease cardiomyopathy"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "IFN-γ and TNF-α signaling, which are constitutively upregulated in CD patients, negatively affect mitochondrial function in cardiomyocytes, recapitulating findings in CCC heart tissue."
    explanation: Documents cytokine-driven cardiomyocyte mitochondrial dysfunction as a distinct step in CCC pathogenesis.
  downstream:
  - target: Myocardial fibrosis and arrhythmogenic substrate
    description: Inflammatory and metabolic injury drives fibrotic remodeling and an arrhythmia substrate.
- name: Myocardial fibrosis and arrhythmogenic substrate
  biological_scale: TISSUE
  conforms_to: "fibrotic_response#Excessive ECM Deposition"
  description: >-
    Chronic inflammation, mitochondrial dysfunction, and cardiomyocyte loss
    produce myocardial fibrosis (excess extracellular matrix), which together with
    these injuries forms the substrate for re-entrant ventricular arrhythmias and
    progressive ventricular remodeling.
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  biological_processes:
  - preferred_term: extracellular matrix organization
    modifier: INCREASED
    term:
      id: GO:0030198
      label: extracellular matrix organization
  evidence:
  - reference: DOI:10.1177/15353702231220658
    reference_title: "Inflammation and mitochondria in the pathogenesis of chronic Chagas disease cardiomyopathy"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Myocardial fibrosis, inflammation, and mitochondrial dysfunction are involved in the arrhythmia substrate and triggering events."
    explanation: Identifies fibrosis (with inflammation and mitochondrial dysfunction) as the arrhythmogenic substrate.
  downstream:
  - target: Ventricular remodeling and dilated cardiomyopathy
    description: Fibrotic injury drives maladaptive ventricular remodeling.
  - target: Ventricular arrhythmia
    description: The fibrotic substrate underlies re-entrant ventricular arrhythmias.
- name: Ventricular remodeling and dilated cardiomyopathy
  biological_scale: TISSUE
  description: >-
    Cumulative fibrosis and cardiomyocyte loss produce maladaptive ventricular
    remodeling and dilated cardiomyopathy — the hallmark chronic manifestation —
    with heart failure and arrhythmia as the fatal endpoints.
  conforms_to: "cardiomyopathy_maladaptive_remodeling#Ventricular Remodeling"
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  biological_processes:
  - preferred_term: cardiac muscle tissue morphogenesis
    modifier: ABNORMAL
    term:
      id: GO:0055008
      label: cardiac muscle tissue morphogenesis
  evidence:
  - reference: DOI:10.1177/15353702231220658
    reference_title: "Inflammation and mitochondria in the pathogenesis of chronic Chagas disease cardiomyopathy"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Death results from heart failure or arrhythmia in a subset of CCC patients."
    explanation: Identifies heart failure and arrhythmia as the fatal endpoints of the remodeling cascade.
  downstream:
  - target: Cardiomyopathy
    description: The remodeling cascade manifests clinically as Chagas cardiomyopathy.
- name: Enteric nervous system denervation
  biological_scale: TISSUE
  description: >-
    Inflammatory invasion of the enteric plexuses causes progressive destruction
    of myenteric (Auerbach) neurons throughout the digestive tract. The resulting
    intrinsic denervation impairs peristalsis and, in a subset of patients,
    produces the digestive megasyndromes (megaesophagus and megacolon).
  biological_processes:
  - preferred_term: neuron apoptotic process
    modifier: INCREASED
    term:
      id: GO:0051402
      label: neuron apoptotic process
  evidence:
  - reference: PMID:20004942
    reference_title: "Characterization of enteroglial cells and denervation process in chagasic patients with and without megaesophagus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Gastrointestinal form of Chagas disease involves an inflammatory invasion of the enteric plexuses and degeneration of enteric neurons"
    explanation: Human pathology study documenting inflammatory enteric-plexus invasion and neuronal degeneration as the digestive-form mechanism.
  - reference: PMID:32338024
    reference_title: "Megacolon with infectious etiology that is infrequent in our country: Chagas disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the digestive form is characterized by megaesophagus and megacolon. There is altered peristalsis due to the destruction of the neurons of the enteric nervous system caused by the parasite."
    explanation: Links enteric-neuron destruction to impaired peristalsis and the megaesophagus/megacolon megasyndromes.
  downstream:
  - target: Megaesophagus
    description: Esophageal denervation produces megaesophagus.
  - target: Megacolon
    description: Colonic denervation produces megacolon.
phenotypes:
- name: Cardiomyopathy
  category: Cardiovascular
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Cardiomyopathy
    term:
      id: HP:0001638
      label: Cardiomyopathy
  evidence:
  - reference: DOI:10.1177/15353702231220658
    reference_title: "Inflammation and mitochondria in the pathogenesis of chronic Chagas disease cardiomyopathy"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "About 30% of CD patients develop chronic Chagas disease cardiomyopathy"
    explanation: About 30% of chronically infected patients develop chronic
      Chagas cardiomyopathy, placing it in the FREQUENT band (30-79%).
  - reference: PMID:28284779
    reference_title: "Heart Transplantation for Chagas Cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Chagas cardiomyopathy (CC) is one of the chronic manifestations of Trypanosoma cruzi (T. cruzi) infection"
    explanation: The abstract identifies cardiomyopathy as a chronic manifestation of Chagas disease.
- name: Heart failure
  category: Cardiovascular
  phenotype_term:
    preferred_term: Congestive heart failure
    term:
      id: HP:0001635
      label: Congestive heart failure
  evidence:
  - reference: PMID:28284779
    reference_title: "Heart Transplantation for Chagas Cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Chagas etiology of heart failure has become the third most common indication for HT in South America."
    explanation: The abstract links Chagas disease to heart failure requiring transplantation.
- name: Myocarditis
  category: Cardiovascular
  description: Acute-phase Trypanosoma cruzi infection can cause myocarditis.
  phenotype_term:
    preferred_term: Myocarditis
    term:
      id: HP:0012819
      label: Myocarditis
  evidence:
  - reference: PMID:25993972
    reference_title: "The Epidemiology, Clinical Manifestations, and Management of Chagas Heart Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In the acute phase, the disease can cause cardiac derangements such as myocarditis, conduction system abnormalities, and/or pericarditis."
    explanation: Review documenting acute myocarditis as an acute-phase cardiac manifestation.
- name: Atrioventricular block
  category: Cardiovascular
  description: >-
    Atrioventricular block is a characteristic conduction-system manifestation of
    Chagas heart disease, occurring in both the acute phase and chronic
    cardiomyopathy, and can progress to complete heart block requiring pacing.
  phenotype_term:
    preferred_term: Atrioventricular block
    term:
      id: HP:0001678
      label: Atrioventricular block
  evidence:
  - reference: PMID:25993972
    reference_title: "The Epidemiology, Clinical Manifestations, and Management of Chagas Heart Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In the acute phase, the disease can cause cardiac derangements such as myocarditis, conduction system abnormalities, and/or pericarditis."
    explanation: Review documenting conduction-system abnormalities (including AV block) as a cardiac manifestation of Chagas disease.
- name: Bundle branch and fascicular block
  category: Cardiovascular
  description: >-
    Right bundle branch block (complete or incomplete), characteristically
    combined with left anterior fascicular block (the bifascicular pattern), is
    the hallmark early ECG finding of Chagas heart disease and a diagnostic clue
    in at-risk populations. Bound to the generic Bundle branch block term because
    HPO lacks a non-complete "right bundle branch block" term (only complete
    HP:0011712 and incomplete HP:6000313).
  phenotype_term:
    preferred_term: Right bundle branch block with fascicular block
    term:
      id: HP:0011710
      label: Bundle branch block
  evidence:
  - reference: PMID:28056014
    reference_title: "Prevalence of Chagas Disease in a U.S. Population of Latin American Immigrants with Conduction Abnormalities on Electrocardiogram."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "including right bundle branch block (RBBB), left anterior or posterior fascicular block (LAFB or LPFB, respectively)"
    explanation: Documents RBBB with fascicular block as the characteristic early conduction abnormality of Chagas heart disease.
- name: Ventricular arrhythmia
  category: Cardiovascular
  description: Ventricular arrhythmias are a major cause of mortality in chronic Chagas cardiomyopathy.
  phenotype_term:
    preferred_term: Ventricular arrhythmia
    term:
      id: HP:0004308
      label: Ventricular arrhythmia
  evidence:
  - reference: PMID:25993972
    reference_title: "The Epidemiology, Clinical Manifestations, and Management of Chagas Heart Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Up to one-half of these patients will develop a cardiomyopathy, which can lead to cardiac failure and/or ventricular arrhythmias, both of which are major causes of mortality."
    explanation: Review linking chronic cardiomyopathy to ventricular arrhythmias and mortality.
- name: Megaesophagus
  category: Gastrointestinal
  description: >-
    Esophageal dilatation from myenteric denervation, part of the digestive form
    of chronic Chagas disease; presents with dysphagia and regurgitation.
  notes: >-
    Granularity note: HPO has no megaesophagus-specific term (as of this
    curation), so this is bound to the closest available parent, HP:0002031
    Abnormal esophagus morphology; a more specific term would warrant a new-term
    request to HPO. This contrasts with megacolon, which has a specific term
    (HP:6000852).
  phenotype_term:
    preferred_term: Megaesophagus
    term:
      id: HP:0002031
      label: Abnormal esophagus morphology
  evidence:
  - reference: PMID:20004942
    reference_title: "Characterization of enteroglial cells and denervation process in chagasic patients with and without megaesophagus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the innervation of the esophageal muscle was substantially reduced in patients with megaesophagus"
    explanation: Human study documenting megaesophagus with reduced esophageal innervation.
- name: Megacolon
  category: Gastrointestinal
  description: >-
    Colonic dilatation from myenteric denervation, part of the digestive form of
    chronic Chagas disease; presents with refractory constipation.
  phenotype_term:
    preferred_term: Megacolon
    term:
      id: HP:6000852
      label: Megacolon
  evidence:
  - reference: PMID:32338024
    reference_title: "Megacolon with infectious etiology that is infrequent in our country: Chagas disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the digestive form is characterized by megaesophagus and megacolon. There is altered peristalsis due to the destruction of the neurons of the enteric nervous system caused by the parasite."
    explanation: Case report documenting megacolon as part of the digestive form of Chagas disease.
- name: Constipation
  category: Gastrointestinal
  description: Refractory constipation is the characteristic symptom of chagasic megacolon.
  phenotype_term:
    preferred_term: Constipation
    term:
      id: HP:0002019
      label: Constipation
  evidence:
  - reference: PMID:32338024
    reference_title: "Megacolon with infectious etiology that is infrequent in our country: Chagas disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "constipation refractory to medical treatment, in the context of megacolon due to Chagas disease"
    explanation: Case report documenting refractory constipation from chagasic megacolon.
treatments:
- name: Benznidazole or nifurtimox antitrypanosomal therapy
  description: >-
    Antiparasitic therapy with benznidazole or nifurtimox, the only two
    WHO-recognized trypanocidal drugs. Efficacy is highest in the acute phase,
    congenital infection, and early chronic (indeterminate) infection; in
    established chronic cardiomyopathy the BENEFIT trial showed it clears
    parasitemia but does not halt cardiac deterioration.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: benznidazole
      term:
        id: CHEBI:133833
        label: benznidazole
    - preferred_term: nifurtimox
      term:
        id: CHEBI:7566
        label: Nifurtimox
  target_mechanisms:
  - target: Intracellular amastigote replication in host cells
    treatment_effect: INHIBITS
    description: Trypanocidal drugs kill replicating T. cruzi, reducing parasite load.
  evidence:
  - reference: PMID:30111183
    reference_title: "Clinical and pharmacological profile of benznidazole for treatment of Chagas disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Currently, only benznidazole (BZN) and nifurtimox are recognized by the World Health Organization as effective drugs for treatment of CD."
    explanation: The review lists benznidazole and nifurtimox as WHO-recognized therapies.
  - reference: PMID:20399979
    reference_title: "Chagas disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "treatment with benznidazole (or nifurtimox) is reasonably safe and effective, and is now recommended for a widened range of patients."
    explanation: Review supporting benznidazole/nifurtimox as reasonably safe and effective for a widened patient range.
  - reference: PMID:26323937
    reference_title: "Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Trypanocidal therapy with benznidazole in patients with established Chagas' cardiomyopathy significantly reduced serum parasite detection but did not significantly reduce cardiac clinical deterioration through 5 years of follow-up."
    explanation: BENEFIT randomized trial; benznidazole cleared parasitemia but did not slow cardiac deterioration in established cardiomyopathy, bounding the benefit of trypanocidal therapy in that setting.
- name: Chagas cardiomyopathy management
  description: >-
    Symptomatic cardiac management for established Chagas heart disease: standard
    heart-failure therapy, amiodarone for ventricular arrhythmias, and
    consideration of an implantable cardioverter-defibrillator; advanced disease
    may require heart transplantation.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: amiodarone
      term:
        id: CHEBI:2663
        label: amiodarone
  target_mechanisms:
  - target: Myocardial fibrosis and arrhythmogenic substrate
    treatment_effect: INHIBITS
    description: >-
      Amiodarone suppresses arrhythmias arising from the fibrotic substrate, and
      ICDs abort sudden death from them; neither reverses the substrate itself.
  evidence:
  - reference: PMID:25993972
    reference_title: "The Epidemiology, Clinical Manifestations, and Management of Chagas Heart Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The treatment of Chagas cardiac disease comprises standard medical therapy for heart failure and amiodarone for ventricular arrhythmias, with consideration for implantable cardioverter-defibrillator."
    explanation: Review describing the standard symptomatic management of Chagas heart disease.
- name: Heart transplantation
  description: >-
    Orthotopic heart transplantation is the definitive therapy for end-stage
    Chagas cardiomyopathy; Chagas disease is now a leading indication for heart
    transplantation in South America.
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: NCIT:C15289
      label: Organ Transplantation
  target_mechanisms:
  - target: Ventricular remodeling and dilated cardiomyopathy
    treatment_effect: INHIBITS
    description: Transplantation replaces the end-stage remodeled heart.
  evidence:
  - reference: PMID:28284779
    reference_title: "Heart Transplantation for Chagas Cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Chagas etiology of heart failure has become the third most common indication for HT in South America."
    explanation: Documents heart transplantation as a major treatment for end-stage Chagas cardiomyopathy.
diagnosis:
- name: Serologic diagnosis (anti-T. cruzi IgG)
  description: >-
    Chronic Chagas disease is confirmed serologically by detecting specific
    anti-Trypanosoma cruzi IgG antibodies, conventionally requiring two positive
    tests using different methods.
  evidence:
  - reference: PMID:25993972
    reference_title: "The Epidemiology, Clinical Manifestations, and Management of Chagas Heart Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Diagnosis is confirmed by serologic testing for specific immunoglobulin G antibodies."
    explanation: Review identifying IgG serology as the confirmatory diagnostic modality for chronic infection.
- name: Molecular diagnosis (T. cruzi PCR)
  description: >-
    PCR detects circulating parasite DNA and is most useful in the acute phase,
    congenital infection, reactivation, and for monitoring trypanocidal treatment
    response; sensitivity is lower in the chronic phase.
  evidence:
  - reference: PMID:26323937
    reference_title: "Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "60.5% had positive results for Trypanosoma cruzi on PCR."
    explanation: BENEFIT trial used blood PCR to detect parasite persistence, illustrating PCR's role in chronic-phase parasite monitoring.
discussions:
- discussion_id: gap_chagas_persistence_vs_autoimmunity
  prompt: >-
    In chronic Chagas cardiomyopathy, how much of the ongoing myocardial injury
    is driven by persistent parasitism versus a self-sustaining autoimmune/
    inflammatory process, and why does clearing parasitemia with benznidazole
    fail to halt cardiac deterioration once cardiomyopathy is established?
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - pathophysiology#Chronic myocardial inflammation and cardiomyopathy
  rationale: >-
    The relative contributions of direct parasite persistence and of an
    immune-mediated (partly autoimmune) response to chronic Chagas cardiomyopathy
    are long debated. The BENEFIT trial sharpened the question: benznidazole
    significantly reduced serum parasite detection but did not reduce cardiac
    clinical deterioration over 5 years, implying that parasite clearance alone
    is insufficient once remodeling is established — consistent with a
    self-sustaining inflammatory/fibrotic process, an irreversibility threshold,
    or treatment given too late in the disease course.
  evidence:
  - reference: PMID:26323937
    reference_title: "Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The role of trypanocidal therapy in patients with established Chagas' cardiomyopathy is unproven."
    explanation: The trial's premise and null clinical result frame the persistence-versus-autoimmunity and treatment-timing controversy.
  proposed_experiments:
  - experiment_id: exp_chagas_early_vs_late_trypanocidal
    name: Trypanocidal therapy timing versus myocardial fibrosis progression
    description: >-
      Compare benznidazole given in the indeterminate phase versus established
      cardiomyopathy, tracking cardiac MRI fibrosis, inflammatory biomarkers, and
      clinical outcomes to test whether an irreversibility threshold explains the
      BENEFIT null and to define the treatment window in which parasite clearance
      still alters cardiac trajectory.
    experiment_type:
      preferred_term: prospective cohort study
- discussion_id: gap_chagas_icd_rct
  prompt: >-
    Do implantable cardioverter-defibrillators and other novel therapies reduce
    mortality in Chagas cardiomyopathy, given the high burden of ventricular
    arrhythmias and sudden death?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - phenotypes#Ventricular arrhythmia
  rationale: >-
    Ventricular arrhythmias are a leading cause of death in Chagas cardiomyopathy,
    and ICDs are used in practice, but the mortality benefit specific to Chagas
    disease has not been established in adequately powered randomized trials.
  evidence:
  - reference: PMID:20399979
    reference_title: "Chagas disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the potential benefits of novel therapies (eg, implantable cardioverter defibrillators) need assessment in prospective randomised trials."
    explanation: Authoritative review naming the ICD evidence gap for Chagas cardiomyopathy.
- discussion_id: gap_chagas_vector_chemosensory_domiciliation
  prompt: >-
    How does evolutionary remodeling of the chemosensory (odorant-receptor)
    repertoire in Rhodnius and other triatomine vectors drive adaptation from
    sylvatic to domestic (domiciliary) habitats, and can this be exploited for
    vector control to reduce human transmission?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - transmission#Triatomine fecal contamination during blood feeding
  rationale: >-
    Vectorial transmission dominates human Chagas disease, and the key driver of
    human exposure is vector domiciliation (triatomines colonizing dwellings). A
    comparative-genomics preprint reports lineage-specific odorant-receptor
    expansions and shifts in selective constraint between sylvatic and
    domiciliary Rhodnius species, suggesting host-seeking/habitat-selection
    chemosensory remodeling underlies domiciliation. Whether these molecular
    signatures translate to behavioral domiciliation and offer control targets
    (e.g., attractants/repellents) is an open, translationally important question.
    Note: this lead rests on a non-peer-reviewed preprint and vector-evolution
    data rather than direct disease mechanism, so it is recorded as a gap rather
    than an asserted mechanism.
  evidence:
  - reference: PPR:PPR1277623
    reference_title: "Evolutionary Dynamics of the Complete Chemosensory Repertoire in Kissing Bugs of the Genus Rhodnius: Divergent Odorant Receptors Contrast with Conserved Gene Families"
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "Several receptors, including Orco, also displayed shifts in selective constraints between sylvatic and domiciliary species, consistent with sensory remodeling associated with adaptation to domestic habitats."
    explanation: Non-peer-reviewed comparative-genomics preprint (in silico evolutionary analysis) reporting chemosensory remodeling linked to domiciliary adaptation; cited as a knowledge-gap lead, not as sole support for a disease-mechanism claim.
environmental:
- name: Domestic triatomine vector control
  presence: protective factor
  description: >-
    Large-scale insecticide-based triatomine (kissing-bug) vector control,
    together with blood-donor screening, has reduced Chagas disease incidence and
    prevalence and is the principal translational target for interrupting
    vectorial transmission (see the vector chemosensory/domiciliation
    knowledge gap).
  evidence:
  - reference: PMID:20399979
    reference_title: "Chagas disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Large-scale vector control programmes and screening of blood donors have reduced disease incidence and prevalence."
    explanation: Authoritative review documenting vector control (and blood-donor screening) as effective transmission-reduction interventions.
clinical_trials:
- name: NCT03378661
  phase: PHASE_II
  description: >-
    BENDITA — proof-of-concept randomized trial of benznidazole monotherapy at
    reduced doses/durations and benznidazole/E1224 (fosravuconazole) combination
    regimens in adults with chronic indeterminate Chagas disease.
  evidence:
  - reference: clinicaltrials:NCT03378661
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the assessment of new BZN-sparing regimens in monotherapy and in combination with E1224."
    explanation: Trial evaluating improved/shorter benznidazole regimens to address current treatment limitations.
- name: NCT04897516
  phase: PHASE_III
  description: >-
    NuestroBen — Phase III non-inferiority trial testing shorter (14- and 28-day)
    benznidazole regimens versus the standard 60-day course in adults with chronic
    Chagas disease, aiming to improve the safety profile.
  evidence:
  - reference: clinicaltrials:NCT04897516
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "NuestroBen will test the hypothesis that shorter treatment regimens of 14 days and 28 days will be non-inferior to the standard 60-day treatment while improving the safety profile."
    explanation: Trial testing whether shorter benznidazole regimens retain efficacy with better tolerability.
references:
- reference: DOI:10.1016/j.lana.2024.100768
  title: 'Chagas disease in the United States: a call for increased investment and collaborative research'
  found_in:
  - Chagas_Disease-deep-research-falcon.md
  findings:
  - statement: 'Chagas disease in the United States: a call for increased investment and collaborative research'
    supporting_text: 'Chagas disease in the United States: a call for increased investment and collaborative research'
- reference: DOI:10.1016/j.lana.2024.100821
  title: 'Retrospect, advances and challenges in Chagas disease diagnosis: a comprehensive review'
  found_in:
  - Chagas_Disease-deep-research-falcon.md
  findings:
  - statement: 'Retrospect, advances and challenges in Chagas disease diagnosis: a comprehensive review'
    supporting_text: 'Retrospect, advances and challenges in Chagas disease diagnosis: a comprehensive review'
- reference: DOI:10.1016/j.lana.2024.100881
  title: The epidemiology of Chagas disease in the Americas
  found_in:
  - Chagas_Disease-deep-research-falcon.md
  findings:
  - statement: The epidemiology of Chagas disease in the Americas
    supporting_text: The epidemiology of Chagas disease in the Americas
- reference: DOI:10.1016/j.lanepe.2024.101040
  title: 'Prevalence of Chagas disease among Latin American immigrants in non-endemic countries: an updated systematic review and meta-analysis'
  found_in:
  - Chagas_Disease-deep-research-falcon.md
  findings:
  - statement: 'Prevalence of Chagas disease among Latin American immigrants in non-endemic countries: an updated systematic review and meta-analysis'
    supporting_text: 'Prevalence of Chagas disease among Latin American immigrants in non-endemic countries: an updated systematic review and meta-analysis'
- reference: DOI:10.1038/s41598-024-58776-3
  title: 'Effect of an exercise-based cardiac rehabilitation program on quality of life of patients with chronic Chagas cardiomyopathy: results from the PEACH randomized clinical trial'
  found_in:
  - Chagas_Disease-deep-research-falcon.md
  findings:
  - statement: To investigate the effect of an exercise-based cardiac rehabilitation program on the quality of life (QoL) of patients with chronic Chagas cardiomyopathy (CCC).
    supporting_text: To investigate the effect of an exercise-based cardiac rehabilitation program on the quality of life (QoL) of patients with chronic Chagas cardiomyopathy (CCC).
    evidence:
    - reference: DOI:10.1038/s41598-024-58776-3
      reference_title: 'Effect of an exercise-based cardiac rehabilitation program on quality of life of patients with chronic Chagas cardiomyopathy: results from the PEACH randomized clinical trial'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: To investigate the effect of an exercise-based cardiac rehabilitation program on the quality of life (QoL) of patients with chronic Chagas cardiomyopathy (CCC).
      explanation: Deep research cited this publication as relevant literature for Chagas Disease.
- reference: DOI:10.1093/infdis/jiab513
  title: Recommendations for Screening and Diagnosis of Chagas Disease in the United States
  found_in:
  - Chagas_Disease-deep-research-falcon.md
  findings:
  - statement: Chagas disease affects an estimated 326 000–347 000 people in the United States and is severely underdiagnosed.
    supporting_text: Chagas disease affects an estimated 326 000–347 000 people in the United States and is severely underdiagnosed.
    evidence:
    - reference: DOI:10.1093/infdis/jiab513
      reference_title: Recommendations for Screening and Diagnosis of Chagas Disease in the United States
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Chagas disease affects an estimated 326 000–347 000 people in the United States and is severely underdiagnosed.
      explanation: Deep research cited this publication as relevant literature for Chagas Disease.
- reference: DOI:10.1177/15353702231220658
  title: Inflammation and mitochondria in the pathogenesis of chronic Chagas disease cardiomyopathy
  found_in:
  - Chagas_Disease-deep-research-falcon.md
  findings:
  - statement: Chagas disease (CD), caused by the protozoan parasite Trypanosoma cruzi, is a neglected disease affecting around 6 million people.
    supporting_text: Chagas disease (CD), caused by the protozoan parasite Trypanosoma cruzi, is a neglected disease affecting around 6 million people.
    evidence:
    - reference: DOI:10.1177/15353702231220658
      reference_title: Inflammation and mitochondria in the pathogenesis of chronic Chagas disease cardiomyopathy
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Chagas disease (CD), caused by the protozoan parasite Trypanosoma cruzi, is a neglected disease affecting around 6 million people.
      explanation: Deep research cited this publication as relevant literature for Chagas Disease.
- reference: DOI:10.1186/s13071-023-05861-7
  title: 'The Pampa del Indio project: sustainable vector control and long-term declines in the prevalence and abundance of Triatoma infestans infected with Trypanosoma cruzi in the Argentine Chaco'
  found_in:
  - Chagas_Disease-deep-research-falcon.md
  findings:
  - statement: The Gran Chaco region is a major hotspot of Chagas disease.
    supporting_text: The Gran Chaco region is a major hotspot of Chagas disease.
    evidence:
    - reference: DOI:10.1186/s13071-023-05861-7
      reference_title: 'The Pampa del Indio project: sustainable vector control and long-term declines in the prevalence and abundance of Triatoma infestans infected with Trypanosoma cruzi in the Argentine Chaco'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: The Gran Chaco region is a major hotspot of Chagas disease.
      explanation: Deep research cited this publication as relevant literature for Chagas Disease.
- reference: DOI:10.1186/s13071-024-06276-8
  title: Insecticidal activity of fluralaner (Exzolt®) administered to Gallus gallus domesticus against triatomines (Hemiptera, Reduviidae, Triatominae)
  found_in:
  - Chagas_Disease-deep-research-falcon.md
  findings:
  - statement: Triatoma infestans, Triatoma brasiliensis, Triatoma pseudomaculata and Rhodnius prolixus are vectors of Trypanosoma cruzi, the etiological agent of Chagas disease.
    supporting_text: Triatoma infestans, Triatoma brasiliensis, Triatoma pseudomaculata and Rhodnius prolixus are vectors of Trypanosoma cruzi, the etiological agent of Chagas disease.
    evidence:
    - reference: DOI:10.1186/s13071-024-06276-8
      reference_title: Insecticidal activity of fluralaner (Exzolt®) administered to Gallus gallus domesticus against triatomines (Hemiptera, Reduviidae, Triatominae)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Triatoma infestans, Triatoma brasiliensis, Triatoma pseudomaculata and Rhodnius prolixus are vectors of Trypanosoma cruzi, the etiological agent of Chagas disease.
      explanation: Deep research cited this publication as relevant literature for Chagas Disease.
- reference: DOI:10.1186/s13071-024-06366-7
  title: Slow recovery rates and spatial aggregation of Triatoma infestans populations in an area with high pyrethroid resistance in the Argentine Chaco
  found_in:
  - Chagas_Disease-deep-research-falcon.md
  findings:
  - statement: The emergence of pyrethroid resistance has threatened the elimination of Triatoma infestans from the Gran Chaco ecoregion.
    supporting_text: The emergence of pyrethroid resistance has threatened the elimination of Triatoma infestans from the Gran Chaco ecoregion.
    evidence:
    - reference: DOI:10.1186/s13071-024-06366-7
      reference_title: Slow recovery rates and spatial aggregation of Triatoma infestans populations in an area with high pyrethroid resistance in the Argentine Chaco
      supports: SUPPORT
      evidence_source: OTHER
      snippet: The emergence of pyrethroid resistance has threatened the elimination of Triatoma infestans from the Gran Chaco ecoregion.
      explanation: Deep research cited this publication as relevant literature for Chagas Disease.
- reference: DOI:10.1371/journal.pntd.0011410
  title: 'Chagas prevention and control in an endemic area from the Argentinian Gran Chaco Region: Data from 14 years of uninterrupted intervention'
  found_in:
  - Chagas_Disease-deep-research-falcon.md
  findings:
  - statement: Chagas Disease (ChD) is a Neglected Tropical Disease (NTD) affecting 6 to 7 million people worldwide, mostly from Latin America.
    supporting_text: Chagas Disease (ChD) is a Neglected Tropical Disease (NTD) affecting 6 to 7 million people worldwide, mostly from Latin America.
    evidence:
    - reference: DOI:10.1371/journal.pntd.0011410
      reference_title: 'Chagas prevention and control in an endemic area from the Argentinian Gran Chaco Region: Data from 14 years of uninterrupted intervention'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Chagas Disease (ChD) is a Neglected Tropical Disease (NTD) affecting 6 to 7 million people worldwide, mostly from Latin America.
      explanation: Deep research cited this publication as relevant literature for Chagas Disease.
- reference: DOI:10.1371/journal.pntd.0012407
  title: 'Prevention of congenital chagas disease by trypanocide treatment in women of reproductive age: A meta-analysis of observational studies'
  found_in:
  - Chagas_Disease-deep-research-falcon.md
  findings:
  - statement: Maternal-foetal transmission of Chagas disease (CD) affects newborns worldwide.
    supporting_text: Maternal-foetal transmission of Chagas disease (CD) affects newborns worldwide.
    evidence:
    - reference: DOI:10.1371/journal.pntd.0012407
      reference_title: 'Prevention of congenital chagas disease by trypanocide treatment in women of reproductive age: A meta-analysis of observational studies'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Maternal-foetal transmission of Chagas disease (CD) affects newborns worldwide.
      explanation: Deep research cited this publication as relevant literature for Chagas Disease.
- reference: DOI:10.17037/pubs.04673813
  title: Development of Rapid Diagnostic Tests for Trypanosoma cruzi Lineage-Specific Serology, Comparative Epidemiology and for Monitoring Efficacy of Chemotherapy
  found_in:
  - Chagas_Disease-deep-research-falcon.md
  findings:
  - statement: Development of Rapid Diagnostic Tests for Trypanosoma cruzi Lineage-Specific Serology, Comparative Epidemiology and for Monitoring Efficacy of Chemotherapy
    supporting_text: Trypanosoma cruzi, the protozoan agent of Chagas disease, is split into six distinct genetic lineages TcI – TcVI, each associated with ecoepidemiological features and transmission cycles, and it has long been proposed that the differing lineages may contribute to the varying clinical forms of Chagas disease.
    evidence:
    - reference: DOI:10.17037/pubs.04673813
      reference_title: Development of Rapid Diagnostic Tests for Trypanosoma cruzi Lineage-Specific Serology, Comparative Epidemiology and for Monitoring Efficacy of Chemotherapy
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Trypanosoma cruzi, the protozoan agent of Chagas disease, is split into six distinct genetic lineages TcI – TcVI, each associated with ecoepidemiological features and transmission cycles, and it has long been proposed that the differing lineages may contribute to the varying clinical forms of Chagas disease.
      explanation: Deep research cited this publication as relevant literature for Chagas Disease.
- reference: DOI:10.3389/fmicb.2024.1393992
  title: 'In vitro diagnostic methods of Chagas disease in the clinical laboratory: a scoping review'
  found_in:
  - Chagas_Disease-deep-research-falcon.md
  findings:
  - statement: Chagas disease (CD), caused by Trypanosoma cruzi, is a global health concern with expanding geographical reach.
    supporting_text: Chagas disease (CD), caused by Trypanosoma cruzi, is a global health concern with expanding geographical reach.
    evidence:
    - reference: DOI:10.3389/fmicb.2024.1393992
      reference_title: 'In vitro diagnostic methods of Chagas disease in the clinical laboratory: a scoping review'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Chagas disease (CD), caused by Trypanosoma cruzi, is a global health concern with expanding geographical reach.
      explanation: Deep research cited this publication as relevant literature for Chagas Disease.
- reference: DOI:10.3389/fpara.2023.1138375
  title: 'Laboratory diagnosis of Trypanosoma cruzi infection: a narrative review'
  found_in:
  - Chagas_Disease-deep-research-falcon.md
  findings:
  - statement: Trypanosoma cruzi infection, currently endemic in 21 countries, is a public health problem not only in the Americas but also in countries with Latin American migrants.
    supporting_text: Trypanosoma cruzi infection, currently endemic in 21 countries, is a public health problem not only in the Americas but also in countries with Latin American migrants.
    evidence:
    - reference: DOI:10.3389/fpara.2023.1138375
      reference_title: 'Laboratory diagnosis of Trypanosoma cruzi infection: a narrative review'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Trypanosoma cruzi infection, currently endemic in 21 countries, is a public health problem not only in the Americas but also in countries with Latin American migrants.
      explanation: Deep research cited this publication as relevant literature for Chagas Disease.
- reference: DOI:10.3389/fpara.2023.1241154
  title: 'Clinical use of molecular methods for Trypanosoma cruzi infection in endemic and non-endemic countries: Benefits, limitations and challenges'
  found_in:
  - Chagas_Disease-deep-research-falcon.md
  findings:
  - statement: Trypanosoma cruziinfection is diagnosed by parasitological, molecular, and serological tests.
    supporting_text: Trypanosoma cruziinfection is diagnosed by parasitological, molecular, and serological tests.
    evidence:
    - reference: DOI:10.3389/fpara.2023.1241154
      reference_title: 'Clinical use of molecular methods for Trypanosoma cruzi infection in endemic and non-endemic countries: Benefits, limitations and challenges'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Trypanosoma cruziinfection is diagnosed by parasitological, molecular, and serological tests.
      explanation: Deep research cited this publication as relevant literature for Chagas Disease.
- reference: DOI:10.3390/ijms25073840
  title: 'Chagas Disease: A Silent Threat for Dogs and Humans'
  found_in:
  - Chagas_Disease-deep-research-falcon.md
  findings:
  - statement: Chagas disease (CD) is a vector-borne Neglected Zoonotic Disease (NZD) caused by a flagellate protozoan, Trypanosoma cruzi, that affects various mammalian species across America, including humans and domestic animals.
    supporting_text: Chagas disease (CD) is a vector-borne Neglected Zoonotic Disease (NZD) caused by a flagellate protozoan, Trypanosoma cruzi, that affects various mammalian species across America, including humans and domestic animals.
    evidence:
    - reference: DOI:10.3390/ijms25073840
      reference_title: 'Chagas Disease: A Silent Threat for Dogs and Humans'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Chagas disease (CD) is a vector-borne Neglected Zoonotic Disease (NZD) caused by a flagellate protozoan, Trypanosoma cruzi, that affects various mammalian species across America, including humans and domestic animals.
      explanation: Deep research cited this publication as relevant literature for Chagas Disease.
- reference: DOI:10.3390/jcm13092565
  title: 'Chagas Disease: Comparison of Therapy with Nifurtimox and Benznidazole in Indigenous Communities in Colombia'
  found_in:
  - Chagas_Disease-deep-research-falcon.md
  findings:
  - statement: For indigenous people in Colombia, high infection rates with Chagas disease (CD) are known.
    supporting_text: For indigenous people in Colombia, high infection rates with Chagas disease (CD) are known.
    evidence:
    - reference: DOI:10.3390/jcm13092565
      reference_title: 'Chagas Disease: Comparison of Therapy with Nifurtimox and Benznidazole in Indigenous Communities in Colombia'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: For indigenous people in Colombia, high infection rates with Chagas disease (CD) are known.
      explanation: Deep research cited this publication as relevant literature for Chagas Disease.
- reference: DOI:10.3390/pathogens13100870
  title: The Functions of Cytokines in the Cardiac Immunopathogenesis of Chagas Disease
  found_in:
  - Chagas_Disease-deep-research-falcon.md
  findings:
  - statement: Clinically, it presents in two distinct phases, acute and chronic.
    supporting_text: Clinically, it presents in two distinct phases, acute and chronic.
    evidence:
    - reference: DOI:10.3390/pathogens13100870
      reference_title: The Functions of Cytokines in the Cardiac Immunopathogenesis of Chagas Disease
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Clinically, it presents in two distinct phases, acute and chronic.
      explanation: Deep research cited this publication as relevant literature for Chagas Disease.
- reference: DOI:10.3390/vaccines12080870
  title: Treatments and the Perspectives of Developing a Vaccine for Chagas Disease
  found_in:
  - Chagas_Disease-deep-research-falcon.md
  findings:
  - statement: Chagas disease (CD) treatment and vaccine development are critical due to the significant health burden caused by the disease, especially in Latin America.
    supporting_text: Chagas disease (CD) treatment and vaccine development are critical due to the significant health burden caused by the disease, especially in Latin America.
    evidence:
    - reference: DOI:10.3390/vaccines12080870
      reference_title: Treatments and the Perspectives of Developing a Vaccine for Chagas Disease
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Chagas disease (CD) treatment and vaccine development are critical due to the significant health burden caused by the disease, especially in Latin America.
      explanation: Deep research cited this publication as relevant literature for Chagas Disease.
- reference: DOI:10.7326/aitc202302210
  title: Chagas Disease
  found_in:
  - Chagas_Disease-deep-research-falcon.md
  findings:
  - statement: Chagas Disease
    supporting_text: Chagas Disease
📚

References & Deep Research

References

21
DOI:10.1016/j.lana.2024.100768
Chagas disease in the United States: a call for increased investment and collaborative research
1 finding
Chagas disease in the United States: a call for increased investment and collaborative research
"Chagas disease in the United States: a call for increased investment and collaborative research"
DOI:10.1016/j.lana.2024.100821
Retrospect, advances and challenges in Chagas disease diagnosis: a comprehensive review
1 finding
Retrospect, advances and challenges in Chagas disease diagnosis: a comprehensive review
"Retrospect, advances and challenges in Chagas disease diagnosis: a comprehensive review"
DOI:10.1016/j.lana.2024.100881
The epidemiology of Chagas disease in the Americas
1 finding
The epidemiology of Chagas disease in the Americas
"The epidemiology of Chagas disease in the Americas"
DOI:10.1016/j.lanepe.2024.101040
Prevalence of Chagas disease among Latin American immigrants in non-endemic countries: an updated systematic review and meta-analysis
1 finding
Prevalence of Chagas disease among Latin American immigrants in non-endemic countries: an updated systematic review and meta-analysis
"Prevalence of Chagas disease among Latin American immigrants in non-endemic countries: an updated systematic review and meta-analysis"
DOI:10.1038/s41598-024-58776-3
Effect of an exercise-based cardiac rehabilitation program on quality of life of patients with chronic Chagas cardiomyopathy: results from the PEACH randomized clinical trial
1 finding
To investigate the effect of an exercise-based cardiac rehabilitation program on the quality of life (QoL) of patients with chronic Chagas cardiomyopathy (CCC).
"To investigate the effect of an exercise-based cardiac rehabilitation program on the quality of life (QoL) of patients with chronic Chagas cardiomyopathy (CCC)."
Show evidence (1 reference)
DOI:10.1038/s41598-024-58776-3 SUPPORT Human Clinical
"To investigate the effect of an exercise-based cardiac rehabilitation program on the quality of life (QoL) of patients with chronic Chagas cardiomyopathy (CCC)."
Deep research cited this publication as relevant literature for Chagas Disease.
DOI:10.1093/infdis/jiab513
Recommendations for Screening and Diagnosis of Chagas Disease in the United States
1 finding
Chagas disease affects an estimated 326 000–347 000 people in the United States and is severely underdiagnosed.
"Chagas disease affects an estimated 326 000–347 000 people in the United States and is severely underdiagnosed."
Show evidence (1 reference)
DOI:10.1093/infdis/jiab513 SUPPORT Human Clinical
"Chagas disease affects an estimated 326 000–347 000 people in the United States and is severely underdiagnosed."
Deep research cited this publication as relevant literature for Chagas Disease.
DOI:10.1177/15353702231220658
Inflammation and mitochondria in the pathogenesis of chronic Chagas disease cardiomyopathy
1 finding
Chagas disease (CD), caused by the protozoan parasite Trypanosoma cruzi, is a neglected disease affecting around 6 million people.
"Chagas disease (CD), caused by the protozoan parasite Trypanosoma cruzi, is a neglected disease affecting around 6 million people."
Show evidence (1 reference)
DOI:10.1177/15353702231220658 SUPPORT Human Clinical
"Chagas disease (CD), caused by the protozoan parasite Trypanosoma cruzi, is a neglected disease affecting around 6 million people."
Deep research cited this publication as relevant literature for Chagas Disease.
DOI:10.1186/s13071-023-05861-7
The Pampa del Indio project: sustainable vector control and long-term declines in the prevalence and abundance of Triatoma infestans infected with Trypanosoma cruzi in the Argentine Chaco
1 finding
The Gran Chaco region is a major hotspot of Chagas disease.
"The Gran Chaco region is a major hotspot of Chagas disease."
Show evidence (1 reference)
DOI:10.1186/s13071-023-05861-7 SUPPORT Other
"The Gran Chaco region is a major hotspot of Chagas disease."
Deep research cited this publication as relevant literature for Chagas Disease.
DOI:10.1186/s13071-024-06276-8
Insecticidal activity of fluralaner (Exzolt®) administered to Gallus gallus domesticus against triatomines (Hemiptera, Reduviidae, Triatominae)
1 finding
Triatoma infestans, Triatoma brasiliensis, Triatoma pseudomaculata and Rhodnius prolixus are vectors of Trypanosoma cruzi, the etiological agent of Chagas disease.
"Triatoma infestans, Triatoma brasiliensis, Triatoma pseudomaculata and Rhodnius prolixus are vectors of Trypanosoma cruzi, the etiological agent of Chagas disease."
Show evidence (1 reference)
DOI:10.1186/s13071-024-06276-8 SUPPORT Other
"Triatoma infestans, Triatoma brasiliensis, Triatoma pseudomaculata and Rhodnius prolixus are vectors of Trypanosoma cruzi, the etiological agent of Chagas disease."
Deep research cited this publication as relevant literature for Chagas Disease.
DOI:10.1186/s13071-024-06366-7
Slow recovery rates and spatial aggregation of Triatoma infestans populations in an area with high pyrethroid resistance in the Argentine Chaco
1 finding
The emergence of pyrethroid resistance has threatened the elimination of Triatoma infestans from the Gran Chaco ecoregion.
"The emergence of pyrethroid resistance has threatened the elimination of Triatoma infestans from the Gran Chaco ecoregion."
Show evidence (1 reference)
DOI:10.1186/s13071-024-06366-7 SUPPORT Other
"The emergence of pyrethroid resistance has threatened the elimination of Triatoma infestans from the Gran Chaco ecoregion."
Deep research cited this publication as relevant literature for Chagas Disease.
DOI:10.1371/journal.pntd.0011410
Chagas prevention and control in an endemic area from the Argentinian Gran Chaco Region: Data from 14 years of uninterrupted intervention
1 finding
Chagas Disease (ChD) is a Neglected Tropical Disease (NTD) affecting 6 to 7 million people worldwide, mostly from Latin America.
"Chagas Disease (ChD) is a Neglected Tropical Disease (NTD) affecting 6 to 7 million people worldwide, mostly from Latin America."
Show evidence (1 reference)
DOI:10.1371/journal.pntd.0011410 SUPPORT Human Clinical
"Chagas Disease (ChD) is a Neglected Tropical Disease (NTD) affecting 6 to 7 million people worldwide, mostly from Latin America."
Deep research cited this publication as relevant literature for Chagas Disease.
DOI:10.1371/journal.pntd.0012407
Prevention of congenital chagas disease by trypanocide treatment in women of reproductive age: A meta-analysis of observational studies
1 finding
Maternal-foetal transmission of Chagas disease (CD) affects newborns worldwide.
"Maternal-foetal transmission of Chagas disease (CD) affects newborns worldwide."
Show evidence (1 reference)
DOI:10.1371/journal.pntd.0012407 SUPPORT Other
"Maternal-foetal transmission of Chagas disease (CD) affects newborns worldwide."
Deep research cited this publication as relevant literature for Chagas Disease.
DOI:10.17037/pubs.04673813
Development of Rapid Diagnostic Tests for Trypanosoma cruzi Lineage-Specific Serology, Comparative Epidemiology and for Monitoring Efficacy of Chemotherapy
1 finding
Development of Rapid Diagnostic Tests for Trypanosoma cruzi Lineage-Specific Serology, Comparative Epidemiology and for Monitoring Efficacy of Chemotherapy
"Trypanosoma cruzi, the protozoan agent of Chagas disease, is split into six distinct genetic lineages TcI – TcVI, each associated with ecoepidemiological features and transmission cycles, and it has long been proposed that the differing lineages may contribute to the varying clinical forms of..."
Show evidence (1 reference)
DOI:10.17037/pubs.04673813 SUPPORT Human Clinical
"Trypanosoma cruzi, the protozoan agent of Chagas disease, is split into six distinct genetic lineages TcI – TcVI, each associated with ecoepidemiological features and transmission cycles, and it has long been proposed that the differing lineages may contribute to the varying clinical forms of..."
Deep research cited this publication as relevant literature for Chagas Disease.
DOI:10.3389/fmicb.2024.1393992
In vitro diagnostic methods of Chagas disease in the clinical laboratory: a scoping review
1 finding
Chagas disease (CD), caused by Trypanosoma cruzi, is a global health concern with expanding geographical reach.
"Chagas disease (CD), caused by Trypanosoma cruzi, is a global health concern with expanding geographical reach."
Show evidence (1 reference)
DOI:10.3389/fmicb.2024.1393992 SUPPORT Other
"Chagas disease (CD), caused by Trypanosoma cruzi, is a global health concern with expanding geographical reach."
Deep research cited this publication as relevant literature for Chagas Disease.
DOI:10.3389/fpara.2023.1138375
Laboratory diagnosis of Trypanosoma cruzi infection: a narrative review
1 finding
Trypanosoma cruzi infection, currently endemic in 21 countries, is a public health problem not only in the Americas but also in countries with Latin American migrants.
"Trypanosoma cruzi infection, currently endemic in 21 countries, is a public health problem not only in the Americas but also in countries with Latin American migrants."
Show evidence (1 reference)
DOI:10.3389/fpara.2023.1138375 SUPPORT Human Clinical
"Trypanosoma cruzi infection, currently endemic in 21 countries, is a public health problem not only in the Americas but also in countries with Latin American migrants."
Deep research cited this publication as relevant literature for Chagas Disease.
DOI:10.3389/fpara.2023.1241154
Clinical use of molecular methods for Trypanosoma cruzi infection in endemic and non-endemic countries: Benefits, limitations and challenges
1 finding
Trypanosoma cruziinfection is diagnosed by parasitological, molecular, and serological tests.
"Trypanosoma cruziinfection is diagnosed by parasitological, molecular, and serological tests."
Show evidence (1 reference)
DOI:10.3389/fpara.2023.1241154 SUPPORT Other
"Trypanosoma cruziinfection is diagnosed by parasitological, molecular, and serological tests."
Deep research cited this publication as relevant literature for Chagas Disease.
DOI:10.3390/ijms25073840
Chagas Disease: A Silent Threat for Dogs and Humans
1 finding
Chagas disease (CD) is a vector-borne Neglected Zoonotic Disease (NZD) caused by a flagellate protozoan, Trypanosoma cruzi, that affects various mammalian species across America, including humans and domestic animals.
"Chagas disease (CD) is a vector-borne Neglected Zoonotic Disease (NZD) caused by a flagellate protozoan, Trypanosoma cruzi, that affects various mammalian species across America, including humans and domestic animals."
Show evidence (1 reference)
DOI:10.3390/ijms25073840 SUPPORT Human Clinical
"Chagas disease (CD) is a vector-borne Neglected Zoonotic Disease (NZD) caused by a flagellate protozoan, Trypanosoma cruzi, that affects various mammalian species across America, including humans and domestic animals."
Deep research cited this publication as relevant literature for Chagas Disease.
DOI:10.3390/jcm13092565
Chagas Disease: Comparison of Therapy with Nifurtimox and Benznidazole in Indigenous Communities in Colombia
1 finding
For indigenous people in Colombia, high infection rates with Chagas disease (CD) are known.
"For indigenous people in Colombia, high infection rates with Chagas disease (CD) are known."
Show evidence (1 reference)
DOI:10.3390/jcm13092565 SUPPORT Human Clinical
"For indigenous people in Colombia, high infection rates with Chagas disease (CD) are known."
Deep research cited this publication as relevant literature for Chagas Disease.
DOI:10.3390/pathogens13100870
The Functions of Cytokines in the Cardiac Immunopathogenesis of Chagas Disease
1 finding
Clinically, it presents in two distinct phases, acute and chronic.
"Clinically, it presents in two distinct phases, acute and chronic."
Show evidence (1 reference)
DOI:10.3390/pathogens13100870 SUPPORT Other
"Clinically, it presents in two distinct phases, acute and chronic."
Deep research cited this publication as relevant literature for Chagas Disease.
DOI:10.3390/vaccines12080870
Treatments and the Perspectives of Developing a Vaccine for Chagas Disease
1 finding
Chagas disease (CD) treatment and vaccine development are critical due to the significant health burden caused by the disease, especially in Latin America.
"Chagas disease (CD) treatment and vaccine development are critical due to the significant health burden caused by the disease, especially in Latin America."
Show evidence (1 reference)
DOI:10.3390/vaccines12080870 SUPPORT Other
"Chagas disease (CD) treatment and vaccine development are critical due to the significant health burden caused by the disease, especially in Latin America."
Deep research cited this publication as relevant literature for Chagas Disease.
DOI:10.7326/aitc202302210
Chagas Disease
1 finding
Chagas Disease
"Chagas Disease"

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 80 citations 2026-04-04T13:02:22.648377

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Chagas disease
  • MONDO ID: (if available)
  • Category: Infectious Disease

Research Objectives

Please provide a comprehensive research report on Chagas disease covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Research Report: Chagas disease (American trypanosomiasis)

Target disease

Chagas disease is a chronic, often lifelong zoonotic infection caused by the protozoan parasite Trypanosoma cruzi. Transmission is classically vector-borne via triatomine (“kissing bug”) feces contaminating skin/mucosa, but important non-vector routes include congenital (vertical), blood transfusion, organ transplantation, and oral/foodborne outbreaks. Infections are frequently silent for years to decades, but a subset progress to chronic cardiac and/or digestive disease with substantial morbidity and mortality. (cucunuba2024theepidemiologyof pages 1-2, cucunuba2024theepidemiologyof pages 7-9)

Domain Key finding Quantitative data Source (author year journal) URL/DOI
Epidemiology Global population at risk in the Americas ~75 million at risk Cucunubá et al. 2024, Lancet Regional Health – Americas (cucunuba2024theepidemiologyof pages 2-3) https://doi.org/10.1016/j.lana.2024.100881
Epidemiology Global number infected 6.26 million (2010) to 6.30 million (2021) by GBD; WHO/PAHO estimates ~5.7 million in 21 endemic countries Cucunubá et al. 2024, Lancet Regional Health – Americas (cucunuba2024theepidemiologyof pages 9-10, cucunuba2024theepidemiologyof pages 10-11) https://doi.org/10.1016/j.lana.2024.100881
Epidemiology Annual incidence WHO/PAHO ~40,000 new infections/year; historical decline from ~200,000/year in early 1990s to ~40,000/year by 2010 Cucunubá et al. 2024, Lancet Regional Health – Americas (cucunuba2024theepidemiologyof pages 2-3, cucunuba2024theepidemiologyof pages 10-11) https://doi.org/10.1016/j.lana.2024.100881
Epidemiology Underdiagnosis and treatment gap >90% undiagnosed overall; ~70% unaware of infection; ~1% receive etiologic treatment Cucunubá et al. 2024, Lancet Regional Health – Americas (cucunuba2024theepidemiologyof pages 2-3, cucunuba2024theepidemiologyof pages 1-2) https://doi.org/10.1016/j.lana.2024.100881
Epidemiology Congenital transmission risk Usually ~1–2% to ~5–6%; meta-analytic estimates ~4.7% and ~2.0%; pooled migrant setting estimate 4.4% Cucunubá et al. 2024, Lancet Regional Health – Americas; de Andrade et al. 2024, Lancet Regional Health – Europe (cucunuba2024theepidemiologyof pages 2-3, cucunuba2024theepidemiologyof pages 3-5, andrade2024prevalenceofchagas pages 1-2) https://doi.org/10.1016/j.lana.2024.100881 ; https://doi.org/10.1016/j.lanepe.2024.101040
Diagnostics Chronic Chagas diagnosis requires serologic confirmation with 2 assays At least 2 different serologic assays; if discordant, add a 3rd test Schijman et al. 2024, Lancet Regional Health – Americas; Lopez-Albizu et al. 2023, Frontiers in Parasitology (schijman2024retrospectadvancesand pages 8-9, schijman2024retrospectadvancesand pages 4-6, lopezalbizu2023laboratorydiagnosisof pages 6-7) https://doi.org/10.1016/j.lana.2024.100821 ; https://doi.org/10.3389/fpara.2023.1138375
Diagnostics Serology performance for chronic disease ELISA sensitivity 77.4–100%; specificity 84.2–100%; chronic-stage tests mean sensitivity 94.66%, specificity 91.76% Ascanio et al. 2024, Frontiers in Microbiology (ascanio2024invitrodiagnostic pages 1-2, ascanio2024invitrodiagnostic pages 8-9) https://doi.org/10.3389/fmicb.2024.1393992
Diagnostics Acute/congenital diagnosis relies on parasite detection or molecular methods PCR sensitivities 58.88–100%; specificities 68.8–100%; qPCR for vertical infection 84.2–100%; microhematocrit preferred in neonates Ascanio et al. 2024, Frontiers in Microbiology; Lopez-Albizu et al. 2023, Frontiers in Parasitology; Schijman et al. 2024, Lancet Regional Health – Americas (ascanio2024invitrodiagnostic pages 1-2, ascanio2024invitrodiagnostic pages 8-9, lopezalbizu2023laboratorydiagnosisof pages 6-7, schijman2024retrospectadvancesand pages 2-3, pinazo2023clinicaluseof pages 1-2) https://doi.org/10.3389/fmicb.2024.1393992 ; https://doi.org/10.3389/fpara.2023.1138375 ; https://doi.org/10.1016/j.lana.2024.100821
Treatment Etiologic therapy is most effective in acute disease Acute-phase cure rate ~60–85% Farani et al. 2024, Vaccines (farani2024treatmentsandthe pages 2-4) https://doi.org/10.3390/vaccines12080870
Treatment Pre-pregnancy trypanocidal therapy prevents congenital transmission OR 0.05 (95% CI 0.01–0.27); pooled congenital Chagas prevalence 0.0% (95% CI 0–0.91%) in offspring of treated women de Moraes et al. 2024, PLOS Neglected Tropical Diseases (moraes2024preventionofcongenital pages 6-8, moraes2024preventionofcongenital pages 4-6, moraes2024preventionofcongenital pages 1-2) https://doi.org/10.1371/journal.pntd.0012407
Treatment Adverse events with benznidazole vs nifurtimox in a recent real-world comparison ≥1 AE: BNZ 65% (79/121) vs NFX 84% (96/115); mean AE duration 0.7 vs 1.7 days; AE intensity 1.1 vs 2.1; 2 dropouts due to AEs in NFX only Kann et al. 2024, Journal of Clinical Medicine (kann2024chagasdiseasecomparison pages 1-2) https://doi.org/10.3390/jcm13092565
Prevention / vector control Añatuya 14-year ecohealth program reduced household infestation Intra-domiciliary infestation 17.9% → 0.2%; peri-domiciliary 20.4% → 3%; 4,193 inspections; 399 households structurally improved Weinberg et al. 2023, PLOS Neglected Tropical Diseases (weinberg2023chagaspreventionand pages 1-2) https://doi.org/10.1371/journal.pntd.0011410
Prevention / vector control Pampa del Indio 9-year intervention reduced infected-vector prevalence T. cruzi infection prevalence in Triatoma infestans 24.1% at baseline → 0.9% at endpoint among 6,397 bugs examined Gürtler et al. 2023, Parasites & Vectors (gurtler2023thepampadel pages 1-2) https://doi.org/10.1186/s13071-023-05861-7
Prevention / vector control Pyrethroid resistance sustains infestation hotspots House infestation 33.8% (2018) and 31.6% (2020); peridomestic 26.4–26.7%; domestic 12.2% → 8.3% Cecere et al. 2024, Parasites & Vectors (cecere2024slowrecoveryrates pages 1-2) https://doi.org/10.1186/s13071-024-06366-7
Quality of life / implementation Exercise-based cardiac rehabilitation improved short-term QoL in CCC At 3 months: physical functioning β=+10.7 (p=0.02), role-physical β=+25.0 (p=0.01), social functioning β=+19.2 (p<0.01); no significant between-group differences at 6 months Vieira et al. 2024, Scientific Reports (vieira2024effectofan pages 1-2, vieira2024effectofan pages 3-4) https://doi.org/10.1038/s41598-024-58776-3

Table: This table compiles high-yield quantitative findings on Chagas disease epidemiology, diagnosis, treatment, and prevention/public-health implementation from the evidence gathered. It is designed as a quick-reference artifact for a research report or disease knowledge base entry.

1. Disease information

1.1 Overview and definitions

Chagas disease is a long-lasting infection in which most acute infections are clinically mild or asymptomatic, followed by a chronic phase that can remain indeterminate for decades; approximately 30–40% of infected individuals develop symptomatic chronic disease, frequently cardiac involvement. (cucunuba2024theepidemiologyof pages 9-10, cucunuba2024theepidemiologyof pages 7-9)

1.2 Synonyms and alternative names

  • American trypanosomiasis (common synonym used in clinical/public-health settings). (cucunuba2024theepidemiologyof pages 1-2)
  • Trypanosoma cruzi infection (etiologic phrasing frequently used in diagnostics and guidelines). (ascanio2024invitrodiagnostic pages 1-2, forsyth2022recommendationsforscreening pages 3-4)

1.3 Key identifiers (ontology / coding)

  • MONDO ID: not retrieved in the tool-based evidence available in this run; MONDO is described as a disease-ontology unification framework, but this specific disease’s MONDO identifier was not captured in the retrieved texts. (cucunuba2024theepidemiologyof pages 2-3)
  • ICD / MeSH / Orphanet / OMIM: not reliably extractable from the retrieved evidence set in this run; therefore not asserted here.

1.4 Evidence source type (patient-level vs aggregated)

Most quantitative estimates in this report come from aggregated sources (systematic reviews, meta-analyses, guideline statements, modeling/GBD estimates, and long-running intervention programs). (cucunuba2024theepidemiologyof pages 2-3, andrade2024prevalenceofchagas pages 1-2, weinberg2023chagaspreventionand pages 1-2, forsyth2022recommendationsforscreening pages 3-4)

2. Etiology

2.1 Primary causes

  • Causative agent: Trypanosoma cruzi, an intracellular protozoan parasite (zoonotic). (cucunuba2024theepidemiologyof pages 1-2)
  • Transmission routes (with quantitative estimates where available):
  • Vector-borne: main driver across the Americas; transmission occurs when triatomines feed and contaminate the bite site with infective feces/urine. (cucunuba2024theepidemiologyof pages 1-2)
  • Congenital: mother-to-child transmission probability often ~1–2% to ~5–6%, with meta-analytic estimates ranging from ~2.0% to ~4.7% depending on period and setting. (cucunuba2024theepidemiologyof pages 2-3, cucunuba2024theepidemiologyof pages 3-5)
  • Transfusion-associated: risk estimated ~10–20% per infected blood unit in endemic countries (with component-specific estimates also reported). (cucunuba2024theepidemiologyof pages 2-3)
  • Organ transplantation: risk varies substantially (reported roughly ~13–75%, depending on organ and setting). (cucunuba2024theepidemiologyof pages 2-3)
  • Oral/foodborne outbreaks: associated with higher clinical severity and reported crude case-fatality rates around ~4–6.5% in compiled series. (cucunuba2024theepidemiologyof pages 9-10)

2.2 Risk factors

Environmental / socioeconomic

  • Living in rural/peri-urban settings with vector-infested housing, often tied to poverty and substandard construction, increases risk of vector-borne transmission; large-scale vector programs target these conditions. (weinberg2023chagaspreventionand pages 1-2, gurtler2023thepampadel pages 1-2)

Demographic / clinical

  • Risk of chronic cardiac disease: approximately 30–40% develop symptomatic chronic disease; about one-third develop chronic cardiac disease, with annual progression rates reported ~2–7% among those at risk in some settings. (cucunuba2024theepidemiologyof pages 9-10, higuita2024chagasdiseasein pages 1-2)

Parasite diversity

  • T. cruzi has multiple discrete typing units (DTUs TcI–TcVI), broadly distributed across the Americas; DTU variability may influence clinical and immunologic phenotypes, but proinflammatory cytokine patterns are described across DTUs. (cucunuba2024theepidemiologyof pages 7-9, albaalvarado2024thefunctionsof pages 8-10)

2.3 Protective factors

  • Preconception etiologic treatment of infected women (benznidazole or nifurtimox) is supported by observational evidence as a protective factor against congenital transmission (see Treatment/Prevention sections). (moraes2024preventionofcongenital pages 1-2)

2.4 Gene–environment (host–pathogen) interactions

  • Disease progression appears to reflect host genetic predisposition interacting with chronic inflammatory signaling. Whole-exome sequencing studies in families with different clinical outcomes have identified rare heterozygous pathogenic variants in mitochondrial and inflammatory genes segregating with chronic Chagas cardiomyopathy (CCC), supporting the hypothesis that cytokine-driven mitochondrial dysfunction in genetically predisposed individuals contributes to severity. (nunes2023inflammationandmitochondria pages 1-2)
  • Candidate host polymorphisms in cytokine/chemokine pathways (e.g., TGFB1, CCR5, IFNG, IL10-related loci) have been reported, but authoritative reviews emphasize that “solid genetic biomarkers are lacking” given dependence on host and parasite biology. (albaalvarado2024thefunctionsof pages 8-10, albaalvarado2024thefunctionsof pages 8-8)

3. Phenotypes (clinical manifestations)

Chagas disease is commonly conceptualized as acute → chronic indeterminate → chronic determinate (cardiac and/or digestive) phenotypes.

3.1 Acute infection

  • Often silent: initial infection is asymptomatic in ~95% of vector-mediated cases. (cucunuba2024theepidemiologyof pages 7-9)
  • Acute infections typically last ~4–8 weeks. (cucunuba2024theepidemiologyof pages 9-10)
  • Suggested HPO terms (examples): Fever (HP:0001945), Periorbital edema (HP:0000520; aligns with Romaña sign when present), Myocarditis (HP:0001637).

3.2 Chronic indeterminate form

  • Indeterminate chronic infection can last decades; 60–70% may never progress to symptomatic disease. (cucunuba2024theepidemiologyof pages 7-9)
  • Suggested HPO terms: Asymptomatic (HP:0003745), Abnormal ECG (HP:0001650).

3.3 Chronic Chagas cardiomyopathy (CCC)

  • CCC is characterized by myocarditis and fibrosis leading to conduction disorders, arrhythmias, and progressive ventricular dilation. (nunes2023inflammationandmitochondria pages 2-3)
  • Clinically, a 2024 cytokine-focused review describes that ~27% of patients develop progressive heart failure with conduction defects, apical aneurysms, thrombi, and reduced ejection fraction. (albaalvarado2024thefunctionsof pages 1-2)
  • Suggested HPO terms: Dilated cardiomyopathy (HP:0001644), Ventricular arrhythmia (HP:0004756), Heart failure (HP:0001635), Bundle branch block (HP:0011710), Apical aneurysm (HP:0031557).

3.4 Digestive Chagas disease

  • Digestive complications (classically megaesophagus/megacolon) are established clinical manifestations; however, robust frequency estimates were not available in the retrieved 2023–2024 primary evidence set used here.
  • Suggested HPO terms: Megacolon (HP:0002563), Esophageal dysmotility (HP:0007047), Dysphagia (HP:0002015), Constipation (HP:0002019).

3.5 Congenital Chagas disease

  • Congenital transmission risk is commonly reported in the low single-digit percent range (see Etiology/Epidemiology). (cucunuba2024theepidemiologyof pages 3-5, andrade2024prevalenceofchagas pages 1-2)
  • Suggested HPO terms: Hepatosplenomegaly (HP:0001433), Neonatal infection (HP:0002715), Myocarditis (HP:0001637).

3.6 Quality-of-life impact (CCC)

A randomized trial (PEACH) in CCC with reduced ejection fraction evaluated SF-36 outcomes. Exercise-based cardiac rehabilitation produced short-term QoL improvements at 3 months (physical functioning β=+10.7; role-physical β=+25.0; social functioning β=+19.2), with no sustained between-group differences at 6 months. (vieira2024effectofan pages 1-2, vieira2024effectofan pages 3-4)

4. Genetic / molecular information

4.1 Causal genes

Chagas disease is infectious rather than Mendelian; there are no single causal human genes.

4.2 Host susceptibility / modifier genetics

  • CCC risk and severity are linked to immune and inflammatory pathways; reported candidate associations include variants in cytokine and chemokine axes (e.g., TGFB1, CCR5, IFNG, IL10 pathway), but consensus biomarkers remain insufficient. (albaalvarado2024thefunctionsof pages 8-10, albaalvarado2024thefunctionsof pages 8-8)
  • WES-based family studies suggest rare variants in mitochondrial and inflammatory genes may modify progression to CCC. (nunes2023inflammationandmitochondria pages 1-2)

4.3 Parasite genetics (clinically relevant diversity)

  • Broad geographic distribution of DTUs (TcI–TcVI) across the Americas is described; DTU variability may influence magnitude of inflammation and clinical patterns, but proinflammatory profiles are described across DTUs. (cucunuba2024theepidemiologyof pages 7-9, albaalvarado2024thefunctionsof pages 8-10)

5. Environmental information

5.1 Environmental and housing factors

  • Household construction and peridomestic ecologies drive vector colonization; interventions coupling surveillance, insecticide application, and structural housing improvements are effective in reducing infestation (see Prevention). (weinberg2023chagaspreventionand pages 1-2)

5.2 Lifestyle factors

Not specifically quantified in the retrieved evidence set.

5.3 Infectious agent

  • Trypanosoma cruzi (protozoan). (cucunuba2024theepidemiologyof pages 1-2)

6. Mechanism / pathophysiology

6.1 Causal chain (CCC-focused)

A contemporary mechanistic model supported by recent reviews is: 1) Persistent low-level infection / antigenic stimulation in chronic disease (low parasitemia but continued immune activation) (nunes2023inflammationandmitochondria pages 1-2) 2) Innate sensing via TLR pathways (e.g., TLR2/4 and endosomal TLR7/9) signaling through MyD88 → NF-κB and inflammasome activation, driving IL-12 and Th1 differentiation (nunes2023inflammationandmitochondria pages 1-2, albaalvarado2024thefunctionsof pages 1-2) 3) Th1-rich myocarditis with high IFN-γ/TNF-α and chemokine-driven recruitment (e.g., CCL5, CXCL9/CXCL10), with CD8+ infiltration (nunes2023inflammationandmitochondria pages 2-3, albaalvarado2024thefunctionsof pages 4-5) 4) Fibrosis and remodeling (TGF-β pathway involvement; ECM regulators such as MMP-2/MMP-9, fibronectin) contributing to conduction disease and ventricular dilation (albaalvarado2024thefunctionsof pages 4-5, albaalvarado2024thefunctionsof pages 7-8) 5) Mitochondrial dysfunction and metabolic impairment in cardiomyocytes: reduced oxidative phosphorylation capacity and high-energy phosphate levels, impaired ATP production; IFN-γ/TNF-α signaling can negatively affect mitochondrial function and redox homeostasis, linking inflammation to bioenergetic failure. (nunes2023inflammationandmitochondria pages 1-2, nunes2023inflammationandmitochondria pages 2-3)

6.2 Key pathways and mediators (ontology suggestions)

  • GO Biological Process (examples): inflammatory response (GO:0006954), cytokine-mediated signaling pathway (GO:0019221), regulation of apoptotic process (GO:0042981), extracellular matrix organization (GO:0030198), collagen fibril organization (GO:0030199), mitochondrial ATP synthesis coupled electron transport (GO:0042776).
  • Cell types (CL examples): CD8-positive T cell (CL:0000625), macrophage (CL:0000235), cardiac fibroblast (CL:0002548), cardiomyocyte (CL:0000746), dendritic cell (CL:0000451).

6.3 Biochemical and immunometabolic abnormalities

  • CCC myocardium shows reduced expression of mitochondrial energy metabolism enzymes, reduced high-energy phosphates and impaired ATP generation; cytokine signaling (IFN-γ/TNF-α) is linked mechanistically to mitochondrial dysfunction and nitro-oxidative stress. (nunes2023inflammationandmitochondria pages 1-2, nunes2023inflammationandmitochondria pages 2-3)

7. Anatomical structures affected

7.1 Primary organ systems

  • Cardiovascular system: myocardium, conduction system (arrhythmias, conduction blocks), progressive ventricular dilation and fibrosis. (nunes2023inflammationandmitochondria pages 2-3)
  • Digestive system: colon and esophagus (megacolon/megaesophagus as recognized chronic phenotypes, though frequencies not extracted from the present evidence set). (forsyth2022recommendationsforscreening pages 3-4)

7.2 UBERON suggestions (examples)

  • Heart (UBERON:0000948), myocardium (UBERON:0002349), cardiac conduction system (UBERON:0004537), esophagus (UBERON:0001043), colon (UBERON:0001155).

8. Temporal development

  • Acute phase: typically 4–8 weeks; often asymptomatic. (cucunuba2024theepidemiologyof pages 9-10, cucunuba2024theepidemiologyof pages 7-9)
  • Chronic phase: prolonged indeterminate stage can last decades; symptomatic progression occurs in ~30–40% overall, with annual progression rates to cardiomyopathy reported ~2–7% in some estimates. (cucunuba2024theepidemiologyof pages 9-10, higuita2024chagasdiseasein pages 1-2, cucunuba2024theepidemiologyof pages 7-9)

9. Inheritance and population

9.1 Epidemiology (2023–2024 prioritized)

  • Americas at risk: ~75 million people. (Cucunubá et al., Sep 2024) (cucunuba2024theepidemiologyof pages 2-3)
  • Global infected: GBD estimates ~6.26 million (2010) increasing slightly to ~6.30 million (2021). (Cucunubá et al., Sep 2024) (cucunuba2024theepidemiologyof pages 10-11)
  • Undiagnosed / unaware: likely >90% undiagnosed overall; ~70% unaware; ~1% receive etiologic treatment. (cucunuba2024theepidemiologyof pages 2-3, cucunuba2024theepidemiologyof pages 1-2)
  • Non-endemic countries (migration-associated prevalence): In Latin American immigrants in non-endemic countries, pooled prevalence ~3.5% overall, with very high prevalence among Bolivian migrants (~21.5%). (de Andrade et al., Nov 2024) (andrade2024prevalenceofchagas pages 1-2)
  • United States: estimated 326,000–347,000 infected; annual congenital infections estimated 22–108; <1% access testing and treatment. (Higuita et al., Jun 2024; Forsyth et al., Oct 2022) (higuita2024chagasdiseasein pages 1-2, forsyth2022recommendationsforscreening pages 1-2)

10. Diagnostics

10.1 Current diagnostic principles

Because parasitemia is high in acute infection but low/intermittent in chronic infection, diagnostic strategy is phase-dependent, illustrated in a 2024 Lancet Regional Health–Americas diagnostic algorithm figure (stage-dependent transition from parasitemia-based tests to serology). (schijman2024retrospectadvancesand media 49150249)

10.2 Chronic infection diagnosis (serology)

WHO/PAHO standard: confirm chronic infection using two assays with different principles; if discordant, perform a third test. A 2024 comprehensive review states: “[WHO] recommends to use at least two assays with different principles to confirm a positive serological result for T. cruzi infection.” (Schijman et al., Aug 2024) (schijman2024retrospectadvancesand pages 8-9, schijman2024retrospectadvancesand pages 4-6)

PAHO/WHO diagnostic standard is operationalized as requiring reactive results on two tests of different principles/antigens, with a third test if only one is reactive. (lopezalbizu2023laboratorydiagnosisof pages 6-7)

10.3 Acute / congenital infection diagnosis

  • Recommended approaches include direct parasitological methods (e.g., microhematocrit) and molecular testing (PCR/qPCR); parasitological methods are operator dependent and can have limited sensitivity, while PCR enables rapid and sensitive detection but is cost/infrastructure intensive. (schijman2024retrospectadvancesand pages 8-9, schijman2024retrospectadvancesand pages 4-6)
  • Microhematocrit is highlighted as preferred for congenital diagnosis in neonates, with serologic follow-up later if early tests are negative. (schijman2024retrospectadvancesand pages 2-3)

10.4 Recent diagnostic performance data (2024)

A 2024 scoping review quantified broad performance ranges: - ELISA sensitivity 77.4–100% and specificity 84.2–100% across studies. (ascanio2024invitrodiagnostic pages 1-2) - PCR-based methods: sensitivity 58.88–100% and specificity 68.8–100%; qPCR mean sensitivity ~82.84% and specificity ~94.01% in the compiled review. (ascanio2024invitrodiagnostic pages 8-9)

10.5 Real-world implementation issues

  • Multi-test algorithms and infrastructure needs contribute to delayed turnaround and loss to follow-up in low-resource settings. (schijman2024retrospectadvancesand pages 4-6)
  • In the U.S., experts note that most commercial labs start with a single IgG assay; ensuring two distinct assays often requires confirming which assay was used and potentially sending specimens to CDC for confirmation. (forsyth2022recommendationsforscreening pages 7-8)

10.6 U.S. screening guidance (authoritative)

A U.S. expert working group recommends testing people born in or with prolonged residence in endemic regions of Mexico/Central/South America, screening family members of those who test positive, and giving special consideration to women of childbearing age and infants born to seropositive mothers. Diagnostic confirmation requires two distinct assays (and a third if discordant). (Forsyth et al., Oct 2022) (forsyth2022recommendationsforscreening pages 1-2, forsyth2022recommendationsforscreening pages 2-3)

11. Outcome / prognosis

  • Once chronic cardiomyopathy is established, some syntheses cite annual mortality up to ~8% and increased death risk (e.g., 1.74×) compared with controls/other cardiomyopathies, underscoring severity and the need for early detection. (cucunuba2024theepidemiologyof pages 10-11, higuita2024chagasdiseasein pages 1-2)

12. Treatment

12.1 Standard etiologic pharmacotherapy

  • Benznidazole (BZN) and nifurtimox (NFX) remain the principal approved etiologic therapies; a 2024 review notes they have been used for ~60 years and that efficacy is highest in acute infection, with a reported ~60–85% cure rate in the acute phase. (Farani et al., Aug 2024) (farani2024treatmentsandthe pages 2-4)

12.2 Chronic-phase effectiveness and “test of cure” limitations

  • Serologic cure in chronic infection is slow and uncommon; a 2024 synthesis reports that “only 15% of patients show negative seroconversion after ten years.” (farani2024treatmentsandthe pages 2-4)
  • The absence of a practical test of cure has motivated guideline incorporation of PCR to detect therapeutic failure in some contexts. (pinazo2023clinicaluseof pages 1-2)

12.3 Safety / adverse events (real-world 2024)

In a Colombian indigenous-community comparison, adverse events occurred in 65% (79/121) of BNZ-treated patients versus 84% (96/115) of NFX-treated patients, with longer and more severe AEs in the NFX group and dropouts due to AEs only in NFX. (Kann et al., Apr 2024) (kann2024chagasdiseasecomparison pages 1-2)

12.4 Preventing congenital Chagas via treatment before pregnancy (2024 meta-analysis)

A 2024 meta-analysis of observational studies found that prior trypanocidal treatment in women of reproductive age strongly reduced congenital transmission, reporting OR 0.05 (95% CI 0.01–0.27) and 0.0% pooled prevalence of congenital Chagas among offspring of treated mothers (95% CI 0–0.91%). (de Moraes et al., Sep 2024) (moraes2024preventionofcongenital pages 4-6, moraes2024preventionofcongenital pages 1-2)

12.5 Recent developments: shortened benznidazole regimens and trials

  • BENDITA (NCT03378661): randomized, masked Phase 2 trial evaluating shortened and alternative benznidazole regimens (including 2- and 4-week strategies and combinations with E1224/fosravuconazole), focusing on sustained PCR clearance and tolerability. (NCT03378661 chunk 1, NCT03378661 chunk 2)
  • NuestroBen (NCT04897516): recruiting Phase 3 non-inferiority trial comparing 2-week and 4-week benznidazole regimens versus standard 8-week therapy, using sustained qualitative PCR negativity through 12 months as the primary efficacy endpoint, and comprehensive safety/adherence endpoints. (NCT04897516 chunk 1, NCT04897516 chunk 2)

MAXO suggestions (examples): antiparasitic therapy (MAXO:0000788), benznidazole administration (as a drug intervention concept), nifurtimox administration, prenatal screening (MAXO:0000934), vector control intervention (MAXO:0000753), cardiac rehabilitation therapy (MAXO:0000554).

13. Prevention

13.1 Primary prevention: vector control and housing improvement

A 14-year ecohealth program in rural Argentina (Añatuya) combining surveillance, insecticide use, health promotion, and community-led structural housing improvements reduced intra-domiciliary infestation from 17.9% to 0.2% and peri-domiciliary infestation from 20.4% to 3%, with 399 households structurally improved. (Weinberg et al., Jun 2023) (weinberg2023chagaspreventionand pages 1-2)

13.2 Sustained surveillance + spraying: parasite-based transmission indices

In the Pampa del Indio project (Argentina, 2007–2016), infection prevalence in Triatoma infestans fell from 24.1% at baseline to 0.9% at endpoint (6,397 bugs examined), aligning with human serosurveys and suggesting interruption of vector-borne transmission. (Gürtler et al., Aug 2023) (gurtler2023thepampadel pages 1-2)

13.3 Challenges: insecticide resistance and hotspot persistence (2024)

A 2024 longitudinal survey in a high pyrethroid-resistance area reported persistent infestation (house infestation 33.8% in 2018 and 31.6% in 2020) with spatially aggregated hotspots; the authors recommend targeting hotspots, house-modification measures, and judicious use of alternative insecticides. (Cecere et al., Jul 2024) (cecere2024slowrecoveryrates pages 1-2)

13.4 Secondary prevention: screening programs

  • In non-endemic settings, pregnancy and blood/organ donation pathways are high-yield points for detection and prevention of congenital/transfusion/transplant transmission. (forsyth2022recommendationsforscreening pages 3-4, hochberg2023chagasdisease pages 4-6)

13.5 Tertiary prevention: preventing complications in established disease

  • Cardiac management (ECG/echo surveillance) is recommended even for asymptomatic confirmed infections to identify indeterminate vs organ involvement and guide follow-up. (forsyth2022recommendationsforscreening pages 3-4)
  • Exercise-based cardiac rehabilitation can improve QoL short-term in CCC (implementation-level supportive intervention). (vieira2024effectofan pages 1-2)

14. Other species / natural disease (One Health)

14.1 Reservoirs and cross-species ecology

Chagas disease involves complex zoonotic cycles; transmission cycles involve many mammalian host species, and T. cruzi infects a wide range of mammals. (cucunuba2024theepidemiologyof pages 1-2, duraesoliveira2024chagasdiseasea pages 2-4)

14.2 Dogs as reservoirs and sentinels

A 2024 One Health review emphasizes dogs as major peridomestic reservoirs and sentinels: dogs “play a major role in the domestic cycle” and develop clinically similar disease to humans, making them useful for surveillance and risk mapping. (Durães-Oliveira et al., Mar 2024) (duraesoliveira2024chagasdiseasea pages 1-2)

Quantitative comparative reservoir evidence from a 2024 dissertation dataset found high and similar lineage-specific seroreactivity in humans (69.5%) and dogs (65.8%) using a rapid test for TcII/V/VI signatures, supporting dogs as highly exposed sentinels in those studied settings. (murphy2024developmentofrapid pages 64-65)

14.3 Emerging One Health interventions

Systemic insecticides targeting domestic animals (especially dogs) are being explored to reduce vector populations and contact; a 2024 vector-control paper cites evidence that treating dogs with fluralaner reduced pyrethroid-resistant T. infestans abundance and T. cruzi infection, highlighting a One Health approach to complement house spraying and surveillance. (pereira2024insecticidalactivityof pages 12-13)

15. Model organisms / model systems

The retrieved evidence set in this run did not include primary-methods descriptions of standard experimental models (e.g., specific mouse strains, in vitro cardiomyocyte systems) beyond mechanistic reviews and some preclinical synthesis; therefore, model-organism details are not exhaustively characterized here. Mechanistic studies nevertheless commonly implicate macrophage/innate sensing pathways and cardiomyocyte mitochondrial dysfunction, supporting use of macrophage infection systems and murine cardiomyopathy models in the field. (nunes2023inflammationandmitochondria pages 1-2, albaalvarado2024thefunctionsof pages 1-2)

Expert opinions and analysis (authoritative sources; 2023–2024 prioritized)

  • A 2024 Lancet Regional Health epidemiology synthesis highlights the ethical and societal challenge of Chagas disease driven by underdiagnosis and undertreatment, noting the vast majority of infections go undiagnosed and only ~1% receive etiologic treatment. (cucunuba2024theepidemiologyof pages 2-3)
  • Diagnostic experts emphasize that no single test is a gold standard for all phases, requiring algorithmic testing (serology for chronic; direct detection/PCR for acute/congenital), and that infrastructure and follow-up losses are major barriers. (ascanio2024invitrodiagnostic pages 1-2, schijman2024retrospectadvancesand pages 4-6)
  • CCC mechanistic reviews increasingly frame disease as an interplay between persistent immune activation, fibrosis/remodeling, and mitochondrial/metabolic impairment, potentially modulated by host genetics. (nunes2023inflammationandmitochondria pages 1-2, albaalvarado2024thefunctionsof pages 4-5)

Visual evidence (diagnostic algorithm and test characteristics)

A 2024 comprehensive diagnostic review provides a stage-dependent diagnostic algorithm (Figure) and tables summarizing assay characteristics and recommended testing strategies, supporting the phase-specific approach described above. (schijman2024retrospectadvancesand media 49150249, schijman2024retrospectadvancesand media 2264cf25, schijman2024retrospectadvancesand media b8b9a0ae)

Notes on limitations of this report

  • Several requested identifier fields (MONDO disease ID, ICD/MeSH/Orphanet/OMIM codes) were not extractable from the retrieved evidence set in this run and are not asserted without direct citation.
  • Some phenotype frequencies (especially digestive manifestations) and many model-organism specifics are recognized as important but were not supported by the current retrieved primary evidence excerpts.

Key references (URLs and publication dates)

  • Cucunubá ZM et al. The Lancet Regional Health – Americas (Sep 2024). https://doi.org/10.1016/j.lana.2024.100881 (cucunuba2024theepidemiologyof pages 2-3)
  • Schijman AG et al. The Lancet Regional Health – Americas (Aug 2024). https://doi.org/10.1016/j.lana.2024.100821 (schijman2024retrospectadvancesand pages 8-9)
  • Ascanio LC et al. Frontiers in Microbiology (Apr 2024). https://doi.org/10.3389/fmicb.2024.1393992 (ascanio2024invitrodiagnostic pages 1-2)
  • de Moraes FCA et al. PLOS Neglected Tropical Diseases (Sep 2024). https://doi.org/10.1371/journal.pntd.0012407 (moraes2024preventionofcongenital pages 1-2)
  • Kann S et al. Journal of Clinical Medicine (Apr 2024). https://doi.org/10.3390/jcm13092565 (kann2024chagasdiseasecomparison pages 1-2)
  • Vieira MC et al. Scientific Reports (Apr 2024). https://doi.org/10.1038/s41598-024-58776-3 (vieira2024effectofan pages 1-2)
  • Cecere MC et al. Parasites & Vectors (Jul 2024). https://doi.org/10.1186/s13071-024-06366-7 (cecere2024slowrecoveryrates pages 1-2)
  • Weinberg D et al. PLOS Neglected Tropical Diseases (Jun 2023). https://doi.org/10.1371/journal.pntd.0011410 (weinberg2023chagaspreventionand pages 1-2)
  • Nunes JPS et al. Experimental Biology and Medicine (Nov 2023). https://doi.org/10.1177/15353702231220658 (nunes2023inflammationandmitochondria pages 1-2)
  • Durães-Oliveira J et al. International Journal of Molecular Sciences (Mar 2024). https://doi.org/10.3390/ijms25073840 (duraesoliveira2024chagasdiseasea pages 1-2)
  • Forsyth CJ et al. Journal of Infectious Diseases (Oct 2022). https://doi.org/10.1093/infdis/jiab513 (forsyth2022recommendationsforscreening pages 1-2)
  • Hochberg NS, Montgomery SP. Annals of Internal Medicine (Feb 2023). https://doi.org/10.7326/aitc202302210 (hochberg2023chagasdisease pages 1-3)

References

  1. (cucunuba2024theepidemiologyof pages 1-2): Zulma M. Cucunubá, Sebastián A. Gutiérrez-Romero, Juan-David Ramírez, Natalia Velásquez-Ortiz, Soledad Ceccarelli, Gabriel Parra-Henao, Andrés F. Henao-Martínez, Jorge Rabinovich, María-Gloria Basáñez, Pierre Nouvellet, and Fernando Abad-Franch. The epidemiology of chagas disease in the americas. Lancet Regional Health - Americas, 37:100881, Sep 2024. URL: https://doi.org/10.1016/j.lana.2024.100881, doi:10.1016/j.lana.2024.100881. This article has 128 citations.

  2. (cucunuba2024theepidemiologyof pages 7-9): Zulma M. Cucunubá, Sebastián A. Gutiérrez-Romero, Juan-David Ramírez, Natalia Velásquez-Ortiz, Soledad Ceccarelli, Gabriel Parra-Henao, Andrés F. Henao-Martínez, Jorge Rabinovich, María-Gloria Basáñez, Pierre Nouvellet, and Fernando Abad-Franch. The epidemiology of chagas disease in the americas. Lancet Regional Health - Americas, 37:100881, Sep 2024. URL: https://doi.org/10.1016/j.lana.2024.100881, doi:10.1016/j.lana.2024.100881. This article has 128 citations.

  3. (cucunuba2024theepidemiologyof pages 2-3): Zulma M. Cucunubá, Sebastián A. Gutiérrez-Romero, Juan-David Ramírez, Natalia Velásquez-Ortiz, Soledad Ceccarelli, Gabriel Parra-Henao, Andrés F. Henao-Martínez, Jorge Rabinovich, María-Gloria Basáñez, Pierre Nouvellet, and Fernando Abad-Franch. The epidemiology of chagas disease in the americas. Lancet Regional Health - Americas, 37:100881, Sep 2024. URL: https://doi.org/10.1016/j.lana.2024.100881, doi:10.1016/j.lana.2024.100881. This article has 128 citations.

  4. (cucunuba2024theepidemiologyof pages 9-10): Zulma M. Cucunubá, Sebastián A. Gutiérrez-Romero, Juan-David Ramírez, Natalia Velásquez-Ortiz, Soledad Ceccarelli, Gabriel Parra-Henao, Andrés F. Henao-Martínez, Jorge Rabinovich, María-Gloria Basáñez, Pierre Nouvellet, and Fernando Abad-Franch. The epidemiology of chagas disease in the americas. Lancet Regional Health - Americas, 37:100881, Sep 2024. URL: https://doi.org/10.1016/j.lana.2024.100881, doi:10.1016/j.lana.2024.100881. This article has 128 citations.

  5. (cucunuba2024theepidemiologyof pages 10-11): Zulma M. Cucunubá, Sebastián A. Gutiérrez-Romero, Juan-David Ramírez, Natalia Velásquez-Ortiz, Soledad Ceccarelli, Gabriel Parra-Henao, Andrés F. Henao-Martínez, Jorge Rabinovich, María-Gloria Basáñez, Pierre Nouvellet, and Fernando Abad-Franch. The epidemiology of chagas disease in the americas. Lancet Regional Health - Americas, 37:100881, Sep 2024. URL: https://doi.org/10.1016/j.lana.2024.100881, doi:10.1016/j.lana.2024.100881. This article has 128 citations.

  6. (cucunuba2024theepidemiologyof pages 3-5): Zulma M. Cucunubá, Sebastián A. Gutiérrez-Romero, Juan-David Ramírez, Natalia Velásquez-Ortiz, Soledad Ceccarelli, Gabriel Parra-Henao, Andrés F. Henao-Martínez, Jorge Rabinovich, María-Gloria Basáñez, Pierre Nouvellet, and Fernando Abad-Franch. The epidemiology of chagas disease in the americas. Lancet Regional Health - Americas, 37:100881, Sep 2024. URL: https://doi.org/10.1016/j.lana.2024.100881, doi:10.1016/j.lana.2024.100881. This article has 128 citations.

  7. (andrade2024prevalenceofchagas pages 1-2): Gisele Nepomuceno de Andrade, Pau Bosch-Nicolau, Bruno R. Nascimento, Francisco Rogerlândio Martins-Melo, Pablo Perel, Yvonne Geissbühler, Caroline Demacq, Monica Quijano, Jonathan F. Mosser, Ewerton Cousin, Ísis Eloah Machado, Matheus Lucca A.C. Rodrigues, Antonio Luiz P. Ribeiro, and Israel Molina. Prevalence of chagas disease among latin american immigrants in non-endemic countries: an updated systematic review and meta-analysis. The Lancet Regional Health - Europe, 46:101040, Nov 2024. URL: https://doi.org/10.1016/j.lanepe.2024.101040, doi:10.1016/j.lanepe.2024.101040. This article has 27 citations.

  8. (schijman2024retrospectadvancesand pages 8-9): Alejandro Gabriel Schijman, Julio Alonso-Padilla, Constança Britto, and Claudia Patricia Herrera Bernal. Retrospect, advances and challenges in chagas disease diagnosis: a comprehensive review. The Lancet Regional Health - Americas, 36:100821, Aug 2024. URL: https://doi.org/10.1016/j.lana.2024.100821, doi:10.1016/j.lana.2024.100821. This article has 60 citations.

  9. (schijman2024retrospectadvancesand pages 4-6): Alejandro Gabriel Schijman, Julio Alonso-Padilla, Constança Britto, and Claudia Patricia Herrera Bernal. Retrospect, advances and challenges in chagas disease diagnosis: a comprehensive review. The Lancet Regional Health - Americas, 36:100821, Aug 2024. URL: https://doi.org/10.1016/j.lana.2024.100821, doi:10.1016/j.lana.2024.100821. This article has 60 citations.

  10. (lopezalbizu2023laboratorydiagnosisof pages 6-7): Constanza Lopez-Albizu, Rocío Rivero, Griselda Ballering, Hector Freilij, María Soledad Santini, and Margarita María Catalina Bisio. Laboratory diagnosis of trypanosoma cruzi infection: a narrative review. Frontiers in Parasitology, May 2023. URL: https://doi.org/10.3389/fpara.2023.1138375, doi:10.3389/fpara.2023.1138375. This article has 23 citations.

  11. (ascanio2024invitrodiagnostic pages 1-2): Luis C. Ascanio, Savannah Carroll, Alberto Paniz-Mondolfi, and Juan David Ramírez. In vitro diagnostic methods of chagas disease in the clinical laboratory: a scoping review. Frontiers in Microbiology, Apr 2024. URL: https://doi.org/10.3389/fmicb.2024.1393992, doi:10.3389/fmicb.2024.1393992. This article has 19 citations and is from a peer-reviewed journal.

  12. (ascanio2024invitrodiagnostic pages 8-9): Luis C. Ascanio, Savannah Carroll, Alberto Paniz-Mondolfi, and Juan David Ramírez. In vitro diagnostic methods of chagas disease in the clinical laboratory: a scoping review. Frontiers in Microbiology, Apr 2024. URL: https://doi.org/10.3389/fmicb.2024.1393992, doi:10.3389/fmicb.2024.1393992. This article has 19 citations and is from a peer-reviewed journal.

  13. (schijman2024retrospectadvancesand pages 2-3): Alejandro Gabriel Schijman, Julio Alonso-Padilla, Constança Britto, and Claudia Patricia Herrera Bernal. Retrospect, advances and challenges in chagas disease diagnosis: a comprehensive review. The Lancet Regional Health - Americas, 36:100821, Aug 2024. URL: https://doi.org/10.1016/j.lana.2024.100821, doi:10.1016/j.lana.2024.100821. This article has 60 citations.

  14. (pinazo2023clinicaluseof pages 1-2): Maria-Jesus Pinazo, Colin J. Forsyth, Constanza Lopez-Albizu, Margarita María Catalina Bisio, Adriana González-Martínez, Laura Bohorquez, Jimy Pinto, Israel Molina, Andrea Marchiol, Rafael Herazo, Irene Losada Galván, Tayná Marques, Fabiana Barreira, Juan Carlos Villar, Yanina Sguassero, Maria Soledad Santini, Jaime Altcheh, Belkisyolé Alarcón de Noya, and Sergio Sosa-Estani. Clinical use of molecular methods for trypanosoma cruzi infection in endemic and non-endemic countries: benefits, limitations and challenges. Frontiers in Parasitology, Nov 2023. URL: https://doi.org/10.3389/fpara.2023.1241154, doi:10.3389/fpara.2023.1241154. This article has 7 citations.

  15. (farani2024treatmentsandthe pages 2-4): Priscila Silva Grijó Farani, Kathryn Marie Jones, and Cristina Poveda. Treatments and the perspectives of developing a vaccine for chagas disease. Vaccines, 12:870, Aug 2024. URL: https://doi.org/10.3390/vaccines12080870, doi:10.3390/vaccines12080870. This article has 15 citations.

  16. (moraes2024preventionofcongenital pages 6-8): Francisco Cezar Aquino de Moraes, Maria Eduarda Cavalcanti Souza, Lucca Dal Moro, Isabelle Batista Donadon, Emanuele Rocha da Silva, Dilma do Socorro Moraes de Souza, and Rommel Mario Rodríguez Burbano. Prevention of congenital chagas disease by trypanocide treatment in women of reproductive age: a meta-analysis of observational studies. PLOS Neglected Tropical Diseases, 18:e0012407, Sep 2024. URL: https://doi.org/10.1371/journal.pntd.0012407, doi:10.1371/journal.pntd.0012407. This article has 19 citations and is from a domain leading peer-reviewed journal.

  17. (moraes2024preventionofcongenital pages 4-6): Francisco Cezar Aquino de Moraes, Maria Eduarda Cavalcanti Souza, Lucca Dal Moro, Isabelle Batista Donadon, Emanuele Rocha da Silva, Dilma do Socorro Moraes de Souza, and Rommel Mario Rodríguez Burbano. Prevention of congenital chagas disease by trypanocide treatment in women of reproductive age: a meta-analysis of observational studies. PLOS Neglected Tropical Diseases, 18:e0012407, Sep 2024. URL: https://doi.org/10.1371/journal.pntd.0012407, doi:10.1371/journal.pntd.0012407. This article has 19 citations and is from a domain leading peer-reviewed journal.

  18. (moraes2024preventionofcongenital pages 1-2): Francisco Cezar Aquino de Moraes, Maria Eduarda Cavalcanti Souza, Lucca Dal Moro, Isabelle Batista Donadon, Emanuele Rocha da Silva, Dilma do Socorro Moraes de Souza, and Rommel Mario Rodríguez Burbano. Prevention of congenital chagas disease by trypanocide treatment in women of reproductive age: a meta-analysis of observational studies. PLOS Neglected Tropical Diseases, 18:e0012407, Sep 2024. URL: https://doi.org/10.1371/journal.pntd.0012407, doi:10.1371/journal.pntd.0012407. This article has 19 citations and is from a domain leading peer-reviewed journal.

  19. (kann2024chagasdiseasecomparison pages 1-2): Simone Kann, Gustavo Concha, Hagen Frickmann, Ralf Matthias Hagen, Philipp Warnke, Ernst Molitor, Achim Hoerauf, and Joy Backhaus. Chagas disease: comparison of therapy with nifurtimox and benznidazole in indigenous communities in colombia. Journal of Clinical Medicine, 13:2565, Apr 2024. URL: https://doi.org/10.3390/jcm13092565, doi:10.3390/jcm13092565. This article has 10 citations.

  20. (weinberg2023chagaspreventionand pages 1-2): Diego Weinberg, Maria Florencia Casale, Rosa Graciela Cejas, Rafael Hoyos, María Victoria Periago, Elsa Segura, and Marcelo Claudio Abril. Chagas prevention and control in an endemic area from the argentinian gran chaco region: data from 14 years of uninterrupted intervention. PLOS Neglected Tropical Diseases, 17:e0011410, Jun 2023. URL: https://doi.org/10.1371/journal.pntd.0011410, doi:10.1371/journal.pntd.0011410. This article has 8 citations and is from a domain leading peer-reviewed journal.

  21. (gurtler2023thepampadel pages 1-2): Ricardo Esteban Gürtler, Gustavo Fabián Enriquez, María Sol Gaspe, Natalia Paula Macchiaverna, María del Pilar Fernández, Lucía Inés Rodríguez-Planes, Yael Mariana Provecho, and Marta Victoria Cardinal. The pampa del indio project: sustainable vector control and long-term declines in the prevalence and abundance of triatoma infestans infected with trypanosoma cruzi in the argentine chaco. Parasites & Vectors, Aug 2023. URL: https://doi.org/10.1186/s13071-023-05861-7, doi:10.1186/s13071-023-05861-7. This article has 7 citations and is from a peer-reviewed journal.

  22. (cecere2024slowrecoveryrates pages 1-2): María Carla Cecere, María Sol Gaspe, Natalia Paula Macchiaverna, Gustavo Fabián Enriquez, Alejandra Alvedro, Mariano Alberto Laiño, Julián Antonio Alvarado-Otegui, Marta Victoria Cardinal, and Ricardo Esteban Gürtler. Slow recovery rates and spatial aggregation of triatoma infestans populations in an area with high pyrethroid resistance in the argentine chaco. Parasites & Vectors, Jul 2024. URL: https://doi.org/10.1186/s13071-024-06366-7, doi:10.1186/s13071-024-06366-7. This article has 5 citations and is from a peer-reviewed journal.

  23. (vieira2024effectofan pages 1-2): Marcelo Carvalho Vieira, Fernanda de Souza Nogueira Sardinha Mendes, Paula Simplício da Silva, Gilberto Marcelo Sperandio da Silva, Flavia Mazzoli-Rocha, Andrea Silvestre de Sousa, Roberto Magalhães Saraiva, Marcelo Teixeira de Holanda, Daniel Arthur Barata Kasal, Henrique Silveira Costa, Juliana Pereira Borges, Michel Silva Reis, Luiz Fernando Rodrigues Junior, Alejandro Marcel Hasslocher-Moreno, Pedro Emmanuel Alvarenga Americano do Brasil, and Mauro Felippe Felix Mediano. Effect of an exercise-based cardiac rehabilitation program on quality of life of patients with chronic chagas cardiomyopathy: results from the peach randomized clinical trial. Scientific Reports, Apr 2024. URL: https://doi.org/10.1038/s41598-024-58776-3, doi:10.1038/s41598-024-58776-3. This article has 5 citations and is from a peer-reviewed journal.

  24. (vieira2024effectofan pages 3-4): Marcelo Carvalho Vieira, Fernanda de Souza Nogueira Sardinha Mendes, Paula Simplício da Silva, Gilberto Marcelo Sperandio da Silva, Flavia Mazzoli-Rocha, Andrea Silvestre de Sousa, Roberto Magalhães Saraiva, Marcelo Teixeira de Holanda, Daniel Arthur Barata Kasal, Henrique Silveira Costa, Juliana Pereira Borges, Michel Silva Reis, Luiz Fernando Rodrigues Junior, Alejandro Marcel Hasslocher-Moreno, Pedro Emmanuel Alvarenga Americano do Brasil, and Mauro Felippe Felix Mediano. Effect of an exercise-based cardiac rehabilitation program on quality of life of patients with chronic chagas cardiomyopathy: results from the peach randomized clinical trial. Scientific Reports, Apr 2024. URL: https://doi.org/10.1038/s41598-024-58776-3, doi:10.1038/s41598-024-58776-3. This article has 5 citations and is from a peer-reviewed journal.

  25. (forsyth2022recommendationsforscreening pages 3-4): Colin J Forsyth, Jennifer Manne-Goehler, Caryn Bern, Jeffrey Whitman, Natasha S Hochberg, Morven Edwards, Rachel Marcus, Norman L Beatty, Yagahira E Castro-Sesquen, Christina Coyle, Paula Stigler Granados, Davidson Hamer, James H Maguire, Robert H Gilman, and Sheba Meymandi. Recommendations for screening and diagnosis of chagas disease in the united states. The Journal of Infectious Diseases, 225:1601-1610, Oct 2022. URL: https://doi.org/10.1093/infdis/jiab513, doi:10.1093/infdis/jiab513. This article has 114 citations.

  26. (higuita2024chagasdiseasein pages 1-2): Nelson Iván Agudelo Higuita, Norman L. Beatty, Colin Forsyth, Andrés F. Henao-Martínez, Jennifer Manne-Goehler, Daniel Bourque, Natalie M. Bowman, Malwina Carrion, Christina Coyle, Madolyn Dauphinais, Kelly DeToy, Robert Gilman, Davidson H. Hamer, Jesica Herick, Salvador Hernandez, Claudia Herrera, Rachel Marcus, Sheba Meymandi, Melissa Nolan, Katherine Reifler, Adrienne Showler, Paula Stigler Granados, Anshule Takyar, Kawsar Talaat, Shilah Waters, and Alyse Wheelock. Chagas disease in the united states: a call for increased investment and collaborative research. The Lancet Regional Health - Americas, 34:100768, Jun 2024. URL: https://doi.org/10.1016/j.lana.2024.100768, doi:10.1016/j.lana.2024.100768. This article has 32 citations.

  27. (albaalvarado2024thefunctionsof pages 8-10): Mariana Citlalli de Alba-Alvarado, Margarita Cabrera-Bravo, Edgar Zenteno, Paz María Salazar-Schetino, and Martha Irene Bucio-Torres. The functions of cytokines in the cardiac immunopathogenesis of chagas disease. Pathogens, 13:870, Oct 2024. URL: https://doi.org/10.3390/pathogens13100870, doi:10.3390/pathogens13100870. This article has 9 citations.

  28. (nunes2023inflammationandmitochondria pages 1-2): João Paulo Silva Nunes, Vinicius Moraes de Paiva Roda, Pauline Andrieux, Jorge Kalil, Christophe Chevillard, and Edecio Cunha-Neto. Inflammation and mitochondria in the pathogenesis of chronic chagas disease cardiomyopathy. Experimental Biology and Medicine, 248:2062-2071, Nov 2023. URL: https://doi.org/10.1177/15353702231220658, doi:10.1177/15353702231220658. This article has 15 citations and is from a peer-reviewed journal.

  29. (albaalvarado2024thefunctionsof pages 8-8): Mariana Citlalli de Alba-Alvarado, Margarita Cabrera-Bravo, Edgar Zenteno, Paz María Salazar-Schetino, and Martha Irene Bucio-Torres. The functions of cytokines in the cardiac immunopathogenesis of chagas disease. Pathogens, 13:870, Oct 2024. URL: https://doi.org/10.3390/pathogens13100870, doi:10.3390/pathogens13100870. This article has 9 citations.

  30. (nunes2023inflammationandmitochondria pages 2-3): João Paulo Silva Nunes, Vinicius Moraes de Paiva Roda, Pauline Andrieux, Jorge Kalil, Christophe Chevillard, and Edecio Cunha-Neto. Inflammation and mitochondria in the pathogenesis of chronic chagas disease cardiomyopathy. Experimental Biology and Medicine, 248:2062-2071, Nov 2023. URL: https://doi.org/10.1177/15353702231220658, doi:10.1177/15353702231220658. This article has 15 citations and is from a peer-reviewed journal.

  31. (albaalvarado2024thefunctionsof pages 1-2): Mariana Citlalli de Alba-Alvarado, Margarita Cabrera-Bravo, Edgar Zenteno, Paz María Salazar-Schetino, and Martha Irene Bucio-Torres. The functions of cytokines in the cardiac immunopathogenesis of chagas disease. Pathogens, 13:870, Oct 2024. URL: https://doi.org/10.3390/pathogens13100870, doi:10.3390/pathogens13100870. This article has 9 citations.

  32. (albaalvarado2024thefunctionsof pages 4-5): Mariana Citlalli de Alba-Alvarado, Margarita Cabrera-Bravo, Edgar Zenteno, Paz María Salazar-Schetino, and Martha Irene Bucio-Torres. The functions of cytokines in the cardiac immunopathogenesis of chagas disease. Pathogens, 13:870, Oct 2024. URL: https://doi.org/10.3390/pathogens13100870, doi:10.3390/pathogens13100870. This article has 9 citations.

  33. (albaalvarado2024thefunctionsof pages 7-8): Mariana Citlalli de Alba-Alvarado, Margarita Cabrera-Bravo, Edgar Zenteno, Paz María Salazar-Schetino, and Martha Irene Bucio-Torres. The functions of cytokines in the cardiac immunopathogenesis of chagas disease. Pathogens, 13:870, Oct 2024. URL: https://doi.org/10.3390/pathogens13100870, doi:10.3390/pathogens13100870. This article has 9 citations.

  34. (forsyth2022recommendationsforscreening pages 1-2): Colin J Forsyth, Jennifer Manne-Goehler, Caryn Bern, Jeffrey Whitman, Natasha S Hochberg, Morven Edwards, Rachel Marcus, Norman L Beatty, Yagahira E Castro-Sesquen, Christina Coyle, Paula Stigler Granados, Davidson Hamer, James H Maguire, Robert H Gilman, and Sheba Meymandi. Recommendations for screening and diagnosis of chagas disease in the united states. The Journal of Infectious Diseases, 225:1601-1610, Oct 2022. URL: https://doi.org/10.1093/infdis/jiab513, doi:10.1093/infdis/jiab513. This article has 114 citations.

  35. (schijman2024retrospectadvancesand media 49150249): Alejandro Gabriel Schijman, Julio Alonso-Padilla, Constança Britto, and Claudia Patricia Herrera Bernal. Retrospect, advances and challenges in chagas disease diagnosis: a comprehensive review. The Lancet Regional Health - Americas, 36:100821, Aug 2024. URL: https://doi.org/10.1016/j.lana.2024.100821, doi:10.1016/j.lana.2024.100821. This article has 60 citations.

  36. (forsyth2022recommendationsforscreening pages 7-8): Colin J Forsyth, Jennifer Manne-Goehler, Caryn Bern, Jeffrey Whitman, Natasha S Hochberg, Morven Edwards, Rachel Marcus, Norman L Beatty, Yagahira E Castro-Sesquen, Christina Coyle, Paula Stigler Granados, Davidson Hamer, James H Maguire, Robert H Gilman, and Sheba Meymandi. Recommendations for screening and diagnosis of chagas disease in the united states. The Journal of Infectious Diseases, 225:1601-1610, Oct 2022. URL: https://doi.org/10.1093/infdis/jiab513, doi:10.1093/infdis/jiab513. This article has 114 citations.

  37. (forsyth2022recommendationsforscreening pages 2-3): Colin J Forsyth, Jennifer Manne-Goehler, Caryn Bern, Jeffrey Whitman, Natasha S Hochberg, Morven Edwards, Rachel Marcus, Norman L Beatty, Yagahira E Castro-Sesquen, Christina Coyle, Paula Stigler Granados, Davidson Hamer, James H Maguire, Robert H Gilman, and Sheba Meymandi. Recommendations for screening and diagnosis of chagas disease in the united states. The Journal of Infectious Diseases, 225:1601-1610, Oct 2022. URL: https://doi.org/10.1093/infdis/jiab513, doi:10.1093/infdis/jiab513. This article has 114 citations.

  38. (NCT03378661 chunk 1): BENDITA BEnznidazole New Doses Improved Treatment and Associations. Drugs for Neglected Diseases. 2016. ClinicalTrials.gov Identifier: NCT03378661

  39. (NCT03378661 chunk 2): BENDITA BEnznidazole New Doses Improved Treatment and Associations. Drugs for Neglected Diseases. 2016. ClinicalTrials.gov Identifier: NCT03378661

  40. (NCT04897516 chunk 1): Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease. Laboratorio Elea Phoenix S.A.. 2021. ClinicalTrials.gov Identifier: NCT04897516

  41. (NCT04897516 chunk 2): Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease. Laboratorio Elea Phoenix S.A.. 2021. ClinicalTrials.gov Identifier: NCT04897516

  42. (hochberg2023chagasdisease pages 4-6): Natasha S. Hochberg and Susan P. Montgomery. Chagas disease. Annals of Internal Medicine, 176:ITC17-ITC32, Feb 2023. URL: https://doi.org/10.7326/aitc202302210, doi:10.7326/aitc202302210. This article has 107 citations and is from a highest quality peer-reviewed journal.

  43. (duraesoliveira2024chagasdiseasea pages 2-4): João Durães-Oliveira, Joana Palma-Marques, Cláudia Moreno, Armanda Rodrigues, Marta Monteiro, Graça Alexandre-Pires, Isabel Pereira da Fonseca, and Gabriela Santos-Gomes. Chagas disease: a silent threat for dogs and humans. International Journal of Molecular Sciences, 25:3840, Mar 2024. URL: https://doi.org/10.3390/ijms25073840, doi:10.3390/ijms25073840. This article has 40 citations.

  44. (duraesoliveira2024chagasdiseasea pages 1-2): João Durães-Oliveira, Joana Palma-Marques, Cláudia Moreno, Armanda Rodrigues, Marta Monteiro, Graça Alexandre-Pires, Isabel Pereira da Fonseca, and Gabriela Santos-Gomes. Chagas disease: a silent threat for dogs and humans. International Journal of Molecular Sciences, 25:3840, Mar 2024. URL: https://doi.org/10.3390/ijms25073840, doi:10.3390/ijms25073840. This article has 40 citations.

  45. (murphy2024developmentofrapid pages 64-65): N Murphy. Development of rapid diagnostic tests for trypanosoma cruzi lineage-specific serology, comparative epidemiology and for monitoring efficacy of chemotherapy. Dissertation, Jan 2024. URL: https://doi.org/10.17037/pubs.04673813, doi:10.17037/pubs.04673813. This article has 0 citations.

  46. (pereira2024insecticidalactivityof pages 12-13): Luanderson Cardoso Pereira, Nathalie de Sena Pereira, Andressa Noronha Barbosa da Silva, Clarice de Freitas Bezerra, Kivia Millana de Sousa, João Ciro Fagundes Neto, George Harisson Felinto Sampaio, Carlos Ramon do Nascimento Brito, Rita de Cássia Moreira Souza, Lúcia Maria da Cunha Galvão, Antônia Claudia Jácome da Câmara, Manuela Sales Lima Nascimento, and Paulo Marcos Matta Guedes. Insecticidal activity of fluralaner (exzolt®) administered to gallus gallus domesticus against triatomines (hemiptera, reduviidae, triatominae). Parasites & Vectors, May 2024. URL: https://doi.org/10.1186/s13071-024-06276-8, doi:10.1186/s13071-024-06276-8. This article has 5 citations and is from a peer-reviewed journal.

  47. (schijman2024retrospectadvancesand media 2264cf25): Alejandro Gabriel Schijman, Julio Alonso-Padilla, Constança Britto, and Claudia Patricia Herrera Bernal. Retrospect, advances and challenges in chagas disease diagnosis: a comprehensive review. The Lancet Regional Health - Americas, 36:100821, Aug 2024. URL: https://doi.org/10.1016/j.lana.2024.100821, doi:10.1016/j.lana.2024.100821. This article has 60 citations.

  48. (schijman2024retrospectadvancesand media b8b9a0ae): Alejandro Gabriel Schijman, Julio Alonso-Padilla, Constança Britto, and Claudia Patricia Herrera Bernal. Retrospect, advances and challenges in chagas disease diagnosis: a comprehensive review. The Lancet Regional Health - Americas, 36:100821, Aug 2024. URL: https://doi.org/10.1016/j.lana.2024.100821, doi:10.1016/j.lana.2024.100821. This article has 60 citations.

  49. (hochberg2023chagasdisease pages 1-3): Natasha S. Hochberg and Susan P. Montgomery. Chagas disease. Annals of Internal Medicine, 176:ITC17-ITC32, Feb 2023. URL: https://doi.org/10.7326/aitc202302210, doi:10.7326/aitc202302210. This article has 107 citations and is from a highest quality peer-reviewed journal.